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The diacylglycerol lipases (DAGL α and β) synthesise 2-AG, the major 
endocannabinoid (eCB) in the developing and adult brain.  2-AG acts most 
prominently on the CB1 and CB2 receptors and growing evidence points to a role of 
eCB signaling in adult neurogenesis as well as a wide range of different 
physiological roles in the brain.  The focus of this thesis is on DAGL driven eCB 
signaling in neural stem cells (NSC).  A role of the eCB system has previously been 
established in migration, proliferation, and neurogenesis.  Here we investigated 
DAGLα and eCB signaling in the context of differentiation.   
The Cor-1 cells were adapted as a NSC model system and can be differentiated into 
glia and neurons.  This differentiation was unaffected by CB signaling.  While DAGLα 
expression is unaffected by glial differentiation, a rapid down regulation of DAGLα 
during neuronal differentiation was detected and we investigated the possibility of 
a specific degradation pathway being involved.  DAGLα has a consensus motif for a 
putative destruction (d-) box that might target DAGL for ubiquitin-proteasome 
mediated degradation.  No evidence was found to support that the d-box is 
involved in DAGLα degradation, however first indications towards degradation 
through the ubiquitin-proteasome pathway were identified.  
What is upstream of eCB signaling in NSCs remains an open question.  The most 
likely candidates are EGF, FGF-2 and insulin and their effect on eCB signaling was 
investigated.  Evidence was found indicating that neither EGF nor FGFR signaling is 
upstream of eCB signaling in Cor-1 cells.  Microarray analysis indicates a potential 
common signaling node between EGFR and eCB signaling.  mTOR was investigated 
in this context, but while we show that mTOR appears to be downstream the EGFR, 
no indication was found that it is downstream of the eCB receptors.  Further 
experiments are needed to determine the relationship between insulin and eCB 
signaling.  It is essential to be able to measure DAGL activity, and a surrogate 
substrate DAGL activity assay was adapted to Cor-1 cells in order to address what is 
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CHAPTER I: INTRODUCTION 
1. Chapter I 
1.1. Endocannabinoid signaling 
1.1.1.  The origins of endocannabinoid research 
The cannabis plant has been used for medical and psychoactive reasons at least for 
several thousand years.  It was discovered in the grave of a Chinese shaman and 
already contained its psychoactive substances (Russo et al., 2008).  In ancient 
Europe, the cannabis plant was mostly used to make the fabric hemp and cordage 
until the knowledge about its psychoactive property was introduced to Europe by 
Napoleon in 1810 (Piomelli, 2003).  The effects of cannabis consumption are 
remarkably diverse and include physiological as well as psychological effects.  
Cannabis has been used as medicine to manage pain and inflammation around the 
world across many centuries, but the psychoactive properties of the plant and a 
failure to isolate the active ingredients, limited its use.  The challenge therefore is to 
understand the signaling of this system to allow separating the medically useful 
from the undesired effects.  
1.1.2. Discovery of the eCB system 
The effects caused by cannabis are mainly mediated by two substances, namely Δ9-
tetrahydrocannabinol (THC) and cannabidiol (CBD).  THC is mainly known for its 
psychoactive properties, whereas CBD has been identified as the main non-
psychoactive substance.  While the study of other plant derived substances like 
morphine were already well advanced, the identification of the active chemical 
within the cannabis plant remained elusive until 1964/65, which is the time when 
the isolation and structural analysis of THC was first reported (Y. Gaoni, 1964; 
Mechoulam and Gaoni, 1965). 
The creation of a selective THC analogue was key to the identification of the 
cannabinoid (CB)-sensitive brain regions (Melvin and Johnson, 1987; Devane et al., 
1988) and led to the cloning of the first two cannabinoid receptors (CB1 and CB2 
receptors) (Matsuda et al., 1990; Munro et al., 1993).  In 1999, the first CB1 
receptor knock out (KO) mouse was presented to the scientific world, with data 
showing that the mutant mice were largely unresponsive to CB drugs.   
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Furthermore, the CB1 receptor was demonstrated to be the mediator of analgesia, 
hypotension and hypothermia as well as having an involvement in the motivational 
aspects of opiates (Ledent et al., 1999).  The creation of a CB2 receptor KO mouse 
followed shortly after (Buckley et al., 2000).  Based on the high expression levels in 
the central nervous system (CNS), the CB1 receptor was thought to be having an 
impact here (Herkenham et al., 1991), whereas the CB2 receptor was associated 
with immune cells (Munro et al., 1993).  The initial dogma, that the CB2 receptor 
does not have a role in the brain, has been revised based on more recent reports 
showing that the CB2 receptor is involved in NSC proliferation in cell culture as well 
as in the adult mouse (Molina-Holgado et al., 2007; Gao et al., 2010).  
The CB1/2 receptors are cell membrane receptors belonging to the receptor family 
of G-protein coupled receptors.  They display a protein sequence similarity of 44% 
(Munro et al., 1993) and, as typical for G-protein coupled receptors, they contain 
seven trans-membrane spanning domains.  These domains are connected via three 
extra- and three intracellular loops.  The N-terminus is located outside the cell, 
while the C-terminus is found within the cell (Pertwee, 2006). Upon stimulation G 
proteins couple to the receptor and are responsible for transmitting the signal 
further.  It is thought that the Gi  alpha subunit, which inhibits the production of 
cAMP from ATP mainly by inhibiting adenylate cyclase and increasing MAPK 
activity, is fundamentally important to this signaling cascade (Pertwee, 2006).  
cAMP is a second messenger and is involved in the regulation of iron as well as 
calcium channels.  Furthermore, it interacts with a wealth of proteins such as PKA, 
PKC, ERK, p38 or Raf-1 (Pagotto et al., 2006).  The downstream mechanisms of the 
CB1/2 receptors are an ever evolving field and is investigated in the context of 
different cells (e.g. Brighton et al., 2011; Merighi et al., 2012).  A recent study 
investigated the signaling of the human CB1 receptor splice variants CB1a and CB1b 
receptors and compared them to the rat CB1 receptor.  They discovered that in 
hippocampal neurons the human CB1 receptors inhibited synaptic transmission less 
compared to the rat CB1 receptor.  This might indicate different downstream 
signaling mechanisms between the rodent and the human CB1 receptors and 
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underlines the importance of investigating the human CB1 receptor (Straiker et al., 
2012). 
 
The hunt for the endogenous CB ligand(s) has identified the lipid anandamide 
(Devane et al., 1992) and 2-arachidonoylglycerol (2-AG) as putative 
endocannabionids (eCBs) (Mechoulam et al., 1995; Sugiura et al., 1995).  2-AG can 
cause THC-typical effects (Mechoulam et al., 1995) and has been argued to be the 
true ligand for the CB1/CB2 receptors based on the observation that it is a full 
agonist (Sugiura et al., 1999).  The paper revealed that 2-AG gave a maximal 
response, which exceeded all other examined compounds and shows activity from 
as little as 0.3nM.  Anandamide was explored and categorized as a partial agonist 
(Sugiura et al., 1999).  
 
Figure 1.1: Structure of eCBs 
Figure adapted from (Matias and Di Marzo, 2007) 
 
Additional receptors and putative eCBs have been discovered.  It has been 
suggested that the G-protein coupled receptor 55 (GPR55) (Baker et al., 2006), the 
transient receptor potential of vannilloid type-1 (TRPV1) (Zygmunt et al., 1999; 
Smart et al., 2000) and the peroxisome proliferators activated receptor (PPAR)α 
(Burstein et al., 2004; Burstein, 2005; Rockwell et al., 2006) are all part of the eCB 
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system.  However, the involvement of GPR55 is largely based on the observation 
that pharmacological agents that act on CB1 and/or CB2 receptors can act on 
GRP55 receptors, and therefore whilst a pharmacologic interaction is established, 
the physiological response requires further study.  The more recently discovered CB 
ligands, noladin ether (Mechoulam et al., 1998; Fezza et al., 2002), virodhamine 
(Porter et al., 2002) and N-arachidonoyldopamine (Bisogno et al., 2000; Hu et al., 
2009) have been shown to be able to activate CB1 and/or CB2 receptors in 
pharmacological assays, but there is as yet no evidence that they do so in a 
physiological context.  If one sticks to a more rigid set of criteria that includes 
evidence of physiological effects, the CB1 and CB2 receptors together with 
anandamide and 2-AG can perhaps be best considered as constituting the core 
identified ligands and receptors of the eCB signaling system. 
In order to establish a more comprehensive understanding of eCB signaling, it is 
crucial to understand how and where the putative eCBs are synthesized and broken 
down, as this will dictate whether they have an opportunity to serve as ligands for 
the CB1/CB2 receptors.  The diacylglycerol lipase (DAGL) homologues α and β were 
shown to synthesize 2-AG from diacylglycerol (DAG) (Bisogno et al., 2003).  2-AG 
levels in the brain are decreased by 80% in DAGLα KO mice and drop by 50% in 
DAGLβ KO mice.  Furthermore, a drastic reduction of arachidonic acid as well as 
anandamide was observed (Gao et al., 2010).  How this is linked to the more 
canonical anandamide biosynthesis from membrane phospholipids via N-
acyltransferase (NAT) and N-Acyl-Phosphatidyledhanolamine-Hydrolysing 
Phospholipase D (NAPE-PLD) is not fully understood yet.  The creation of 
monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH) KO animals 
allowed for clear answers to the question as to how the eCBs are further 
metabolised.  Anandamide seems to be predominantly degraded by FAAH (Cravatt 
et al., 2001), while 2-AG can be broken down to arachidonic acid by MAGL 
(Schlosburg et al., 2010), a process which links the eCB signaling to prostaglandin 
signals (Nomura et al., 2011).  While this seems to be the main degradation 
pathway for 2-AG, metabolism/degradation via other pathways has been described 
by FAAH or cyclooxygenase (COX)-2 (Sugiura et al., 2002).  Together this shows the 
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complexity of eCB signaling as well as the interaction with a multitude of other 
signaling pathways.   
1.1.3. Identification and characterization of DAGL signaling 
The two human DAGL isoforms α and β were first cloned in 2003 and identified as 
the enzymes to synthesize 2-AG from DAG (Bisogno et al., 2003).  2-AG has been 
identified to be the key eCB in many physiological contexts such as axonal growth 
and guidance, as a retrograde messenger at synapses and in adult neurogenesis all 
of which are discussed below.   
DAGL activity was first studied in the context of arachidonic acid released from 
platelets.  The observed lipid release involves DAGL as well as phospholipase C (PLC) 
activity and could be stimulated with calcium (Bell et al., 1979).  Metabolism of DAG 
to arachidonic acid was identified as a two step mechanism shortly afterwards.  
First, DAG is hydrolysed to 2-AG at the sn-1 position.  Second, MAGL metabolizes 2-
AG further to arachidonic acid (Prescott and Majerus, 1983).  Alongside MAGL, 
DAGL was first attempted to be purified from the bovine brain.  Its activity was 
identified to be adenosine triphosphate (ATP) dependent displaying a more potent 
inhibitory activity compared to adenosine diphosphate (ADP) or 
adenosinmonophosphate (AMP), whilst cyclic adenosine monophosphate (cAMP) 
marginally increased activity (Farooqui et al., 1984).  It was purified from bovine 
brain microsomes and showed a molecular weight of 27 kDa when run on a sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).  At low 
concentrations, neither calcium nor magnesium had an effect on enzyme activity 
but a threefold increase was observed after phosphorylation by a cAMP-dependent 
protein kinase (Rosenberger et al., 2007).  This became relevant to neuroscience, 
when the DAGL-MAGL pathway was demonstrated to release arachidonic acid from 
cultured dorsal root ganglion neurons (Allen et al., 1992). 
Especially earlier DAGL studies relied heavily on the semi-selective DAGL inhibitor 
RHC80267 (Sutherland and Amin, 1982), which also displays a considerable efficacy 
towards other serine lipases.  When comparing another DAGL inhibitor 
tetrahydrolipstatin (THL) with RHC80267, a minimal overlap of target profiles was 
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seen; indicating that an effect seen by both drugs has a high likelihood to be a 
DAGL-dependent event.  In the case of a known CB1/CB2 receptor dependent 
event, RHC80267 remains helpful regarding the differentiation between a 2-AG and 
anandamide mediated event (Hoover et al., 2008).  THL, also more commonly 
known as orlistat is known for its inhibition of pancreatic lipase.  This lipase is well 
studied in the context of weight loss (Hadvary et al., 1991) and THL is currently sold 
as an over the counter weight loss aid in the UK.  A THL analogue (OMDM-188) 
promises to be the next generation of DAGL inhibitors due to its high specificity 
(Ortar et al., 2008). 
1.1.4. Cloning of DAGLα and DAGLβ and creation of KO mice 
The human DAGLs were identified by comparing the DNA sequence of a known 
mono-and diglycerol lipase (MDGL) from Penicillium camembertii to the human 
genome (Yamaguchi et al., 1991; Bisogno et al., 2003).  Peniccillia are known to be 
good producers of lipases and are extensively studied for that reason.  MDGL and 
other lipases have a wide range of industrial potential (Ning Li, 2010).  MDGL was 
not able to use triglycerols as a substrate and displayed a unique specificity for 
acylglycerols (Yamaguchi et al., 1991; Bisogno et al., 2003).  The catalytic amino 
acids of this 276 amino acid containing protein were identified by site directed 
mutagenesis and Yamaguchi et al. developed an efficient expression system after 
another attempt in Sacchraromyces cerevisiae failed based on high glycosylation 
levels (Yamaguchi et al., 1992; Yamaguchi et al., 1997).  Mono- and diacylglycerols 
are food emulsifiers and are also used in cosmetics and pharmaceuticals and 
therefore are of interest to several industries.  Furthermore, they are building 
blocks in the synthesis of glycolipids and phospholipids, as well as some prodrugs 






Figure 1.2: Exon structure and overall domain structure of DAGLα and β 
The exon structure of the drosophila DAGL and the vertebrate DAGLα/β are shown 
as a linear schematic.  Vertical lines indicate the exon boundary locations with bold 
lines indicating conservation between the three enzymes.  The 4TM region is shown 
in blue, the catalytic domain in red, and the tail region in green.  A cysteine rich 
sequence is highlighted in yellow and the regulatory loop, encoded by a single exon, 
is shown in green.  A schematic representation of the domain structure is shown 
below the linear schematic and the same colour scheme was used as described 
above (Reisenberg et al., In Print). 
Human DAGLα is the larger of the two enzymes, containing 1042 amino acids (120 
kDa) compared to 672 amino acids (70 kDa) of DAGLβ.  The main difference 
between DAGLα and β can be found after the catalytic domain in the tail region.  
Both proteins have a lipase-3 motif, a serine lipase motif and a four membrane-
spanning domain with the catalytic domain as well as the N-Terminus located 
within the cell.  The two enzymes display a remarkable homology, with a very high 
conservation between man and mouse (Bisogno et al., 2003).   
During development, the DAGLs are expressed in the axonal tracts, while they are 
restricted to dendritic fields in the adults.  This location change goes hand in hand 
with a switch in functionality between development and adulthood.  DAGLα is 
necessary for axonal growth and guidance during development, while in the adult it 
is involved in synaptic transmission (see below for more information).  TaqMan RT-
PCR was used to establish the DAGLα transcript levels in different mouse and 
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human tissue.  It most prominently is expressed in the brain and spinal cord of 
mice.  In the human its expression peaks in the brain and pancreas (Bisogno et al., 
2003), where DAGL activity has been reported to be involved in amylase secretion 
(Hou et al., 1997).   
Given the pharmacological limitations of the available drugs, it was essential to 
create DAGL KO mice to test their function in eCB signaling.  Two separate models 
were published within one day from each other (Gao et al., 2010; Tanimura et al., 
2010).  In DAGLα KO mouse brains and the spinal cord, an 80% reduction in 2-AG 
levels was observed while a 50% reduction was seen in DAGLβ KO mouse brains.  
However, DAGLβ seems to have a significant role in the liver, as 2-AG levels are 
reduced by 90% in DAGLβ KO mice.  Arachidonic acid levels changed in parallel to 2-
AG, displaying a DAGL dependency of its steady state level.  Furthermore, 
anandamide levels were also reduced (Gao et al., 2010).  This most probably relates 
to a complex interplay between the steady-state levels of various arachidonate 
containing lipids rather than a direct role of the DAGLs in the “on-demand” 
synthesis of anandamide (reviewed in Di Marzo, 2011).  Despite many efforts and 
candidate pathways, the pathways regulating the “on-demand” synthesis of 
anandamide are still not fully understood (Alger, 2012).  Nevertheless, the DAGL KO 
mice provide us with an excellent tool to establish the role of these enzymes in eCB 
pathways.  As will be discussed below, they have revealed an essential role for 
DAGLα in retrograde synaptic signaling throughout the brain, and a role for DAGLα 
and DAGLβ in the control of adult neurogenesis.  
1.1.5. The influence of DAGL-dependent eCB signaling on axonal growth 
and guidance 
During development a variety of different processes have to take place to create a 
functional brain.  These processes include differentiation, migration, synapse 
formation and axonal growth and guidance.  Here, we will describe the role the eCB 
system plays in axonal growth and guidance.  This is the process by which neurons 
extend their axons with the help of different guidance clues to find and innervate 
their appropriate targets. 
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Cell adhesion molecules (CAM) such as neural CAM (NCAM), N-cadherin and L1 are 
most prominently known for their adhesive properties, but their ability to signal via 
second messenger cascades is also required to promote a variety of biological 
processes (Cavallaro and Dejana, 2011).  They have been shown to act as surrogate 
ligands for the FGFR (fibroblast growth factor receptor) and by doing so trigger 
calcium influx into the growth cone.  This influx of calcium is necessary and 
sufficient to promote axonal growth and guidance.  FGFR activation stimulates a 
PLCƴ-dependent synthesises of DAG, the substrate of the DAGLs.  Inhibition of 
DAGL can furthermore abolish neurite outgrowth stimulated by the above CAMs.  
This mechanism was shown to operate upstream of calcium influx into growth 
cones via N and L-type calcium channels (Williams et al., 1994b; Williams et al., 
1994a; Hall et al., 1996; Walsh and Doherty, 1997).  FGF (fibroblast growth factor) 
can also stimulate neurite outgrowth through the same activation of PLCƴ as well as 
DAGL to stimulate calcium influx into growth cones (Williams et al., 1994b).   
DAGLα and β are coexpressed in the axonal tracts during development (Bisogno et 
al., 2003).  They are expressed in the same growth cones as the CB1 receptor at this 
stage of development (Berghuis et al., 2007) and CB1 receptor function has been 
identified to be downstream of N-cadherin and FGF2 signaling, but upstream of the 
observed calcium influx (Williams et al., 2003).  The DAGLs generate 2-AG, which 
has also been shown to act as an autocrine signal in vivo in pyramidal cell axons.  
eCB signaling is required for developing pyramidal cells for axonal elongation and 
fasciculation and moreover CB1 receptor null mice , and pyramidal cell specific 
conditional CB1 receptor deficient mice furthermore display impairments in axonal 
fasciculation (Mulder et al., 2008).  The CB1 receptor is also abundantly present in 
axonal growth cones of ƴ-aminobutyric acid (GABA)ergic interneuron during rodent 
cortex development.  The Harkany lab also established that target selection is 
impaired when the CB1 receptor is specifically deleded from GABAergic 
interneurons (Berghuis et al., 2007).  The 2-AG degrading enzyme MAGL appears to 
be used to fine tune 2-AG signaling in the context of axonal growth and guidance.  
MAGL is expressed during development in the axonal tracts but is excluded from 
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the growth cone.  This expression pattern helps 2-AG mediated axonal growth 
(Keimpema et al., 2010).  
 
Figure 1.3: The role of the eCB system for axonal growth and guidance 
This is a simplified model of eCB signaling in the context of axonal guidance.  The 
FGFR is activated and stimulates PLCƴ, which generates 2-AG from DAG.  2-AG then 
activates the CB1 receptor in an autocrine fashion which in turn leads to an internal 
calcium increase via L-& N-type calcium channels. 
 
The exact mechanism of how DAGL/eCB signaling influences calcium influx is not 
fully understood and seems to be context dependent.  While some research points 
towards a Gi-dependent mechanism, based on the observation that calcium influx 
can be inhibited with pertussis toxin (Sugiura et al., 1996), others found that CB1 
receptor agonist dependent calcium influx was not inhibited by the use of pertussis 
toxin, indicating a Gi-independent mechanism (Rubovitch et al., 2002).  Together 
this data provides evidence for a CAM/FGFR dependent calcium influx into growth 
cones via a DAGL dependent eCB signaling pathway, but further research is needed 
to understand the exact mechanism. 
Whether eCB signaling promotes or inhibits axonal growth is context dependent.  
FGF-2 and CAM signaling have been demonstrated to promote axonal growth and 
guidance via a DAGL dependent eCB cascade (Williams et al., 2003; Keimpema et 
al., 2010).  However, in other scenarios growth cone collapse was triggered by CB1 
28 
 
receptor agonist exposure (Berghuis et al., 2007; Argaw et al., 2011).  The upstream 
guidance clues such as FGF2 also have the ability to promote or inhibit axonal 
growth.  Cerebellar granule cells which are grown on laminin and 3T3 fibroblasts 
show increased neurite outgrowth in the presence of FGF-2 concentrations.  The 
opposite is seen using the same experimental setup where the cells are grown on 
an astrocyte monolayer (Williams et al., 1995).  These results indicate that neurite 
outgrowth is highly dependent on the context the cells are exposed to. 
Given the importance of the eCB system for axonal growth and guidance it is 
surprising that the CB1 receptor KO mice, as well as the DAGLα KO mice, were 
overall healthy without any obvious serious defects in the brain (Ledent et al., 1999; 
Gao et al., 2010).  One answer to this might be the high redundancy of ligands and 
receptors.  In the absence of one of the ligands or receptors, the cells might be able 
to compensate by signaling via an alternative signaling route.  This might mean, that 
a multitude of genes have to be knocked out before any effect can be seen.  
Another noteworthy aspect is to consider the context the signaling pathway is 
researched in.  Older CB1 receptor KO mice have shown an increased decline in 
spatial learning as well as a neuronal loss in the hippocampus (Albayram et al., 
2011).  Younger CB1 receptor KO mice are relatively normal, and the full effect can 
only be seen in older animals suggesting that the full effect of the receptors loss can 
only be observed later on in life of the animals.  The full effect of the CB1 receptor 
KO in younger mice therefore is masked and could have been overlooked without 
the use of the older mice.  We also have to remind ourselves of the complexity of 
the human brain, where even a small miswiring might lead to diseases as severe as 
Schizophrenia (Rapoport et al., 2005). 
1.1.6. The role of DAGL in synaptic plasticity 
It often occurs that the same pathways which regulate axonal growth and guidance 
also regulate synapse plasticity (Frank and Tsai, 2009).  This also holds true for 
DAGL dependent eCB signaling.  Synaptic plasticity is the change in connectivity 
between neurons, which depends on experience and is thought to be the 
underlying mechanism for learning and memory (J. C. ECCLES, 1951).  A key aspect 
of trans-synaptic regulation is retrograde signaling, which describes the process by 
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which the molecule travels across the synaptic cleft from the postsynapse back to 
the presynapse.  Different molecules have been suggested to act as retrograde 
messengers including carbon monoxide (Alkadhi et al., 2001), platelet derived 
factor (Kato et al., 1994), arachidonic acid (Malenka and Bear, 2004), and the brain 
derived neurotrophic factor (BDNF) (reviewed Regehr et al., 2009).  The eCBs are 
also a key class of retrograde messengers in the mammalian brain (discussed 
below).   
There are different forms of retrograde neuronal plasticity, and overall they are 
generally distinguished by the nature of the stimuli which induce them.  As 
mentioned above, there is a variety of different stimuli, which are involved in 
retrograde signaling.  DSE and DSI are the depolarization-induced suppression of 
excitation or inhibition respectively (Straiker and Mackie, 2005).  Both DSI and DSE 
occur throughout different brain regions, and DSE has been reported in the 
hippocampus, hypothalamus and the striatum, while DSI was demonstrated in the 
neocortex, cerebellum as well as the substantia nigra (reviewed in Hashimotodani 
et al., 2007b).  Other forms of stimulation are the high-frequent stimulation which 
increases synaptic strength (long term potentiating; LTP) and a low frequency 
stimulation causing synaptic weakening (long term depression, LTD).  The role of 
the eCB system for these forms of synapse plasticity has been described in 
considerable detail elsewhere (Hashimotodani et al., 2007b; Kano et al., 2009).  
Both forms of synaptic plasticity can be potentially found at every excitatory 
synapse of the mammalian brain (Malenka and Bear, 2004).  Further mechanisms 
are metabotropic suppression of inhibition/excitation (MSI/MSE), which describes a 
form of neuronal plasticity via metabotropic glutamate receptors (mGluR).  In 
neocortical interneurons, a 2-AG dependent CB1 receptor activation within the 
same cell has been described and named slow self inhibition (SSI) (Marinelli et al., 
2008).   
The components of the eCB system are ideally located for their role in synaptic 
plasticity driven by retrograde signaling.  Generally speaking, in the context of 
synapse plasticity 2-AG is thought to be synthesized by DAGL in dendritic spines of 
excitatory neurons and is discharged into the synaptic cleft where it mainly 
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interacts with CB1 receptors located at the pre-synaptic terminal.  2-AG signaling is 
then terminated by MAGL, which is also often expressed presynaptically (reviewed 
in Oudin et al., 2011a).  A fundamental switch in DAGL expression occurs between 
development and the adult brain.  While DAGLα is expressed in the axonal tracts 
during the development, it is excluded from the same tracts in the adult and 
becomes highly enriched in dendrites (Bisogno et al., 2003).  This switch in location 
allows for a switch in function.  A very comprehensive study investigating the 
expression of DAGLα in the rat brain was carried out and identified a widespread 
distribution of the enzyme in tune with its role in synapse plasticity throughout the 
brain (Suarez et al., 2011).  CB1 receptor is mainly expressed in the same brain 
regions (Herkenham et al., 1991), ensuring that 2-AG is highly accessible to the 
receptor.  To regulate 2-AG signaling, MAGL was originally thought to be expressed 
mainly in the presynaptic terminals of neurons capable of eCB signaling (Gulyas et 
al., 2004), but it is also now know to be expressed in surrounding synapses and 
astrocytes cells as well (Uchigashima et al., 2011), with expression in the astrocytes 
also regulating the duration of the retrograde signal.  A more detailed description of 
eCB expression in this context can be found elsewhere (Oudin et al., 2011a). 
Hippocampal DSI and cerebellar DSE and DSI have been shown to be mediated 
through a depolarisation induced eCB release from the dendritic spines which 
inhibit the release of neurotransmitter by interacting with presynaptic CB1 
receptors (Kreitzer and Regehr, 2001; Ohno-Shosaku et al., 2001; Wilson et al., 
2001).  The inhibition of the neurotransmitter release is usually a consequence of 
brief CB1 receptor stimulation which induces an inhibition of voltage-gated calcium 
channels and other studies have reported an increase in potassium conductance 




Figure 1.4:  eCB mediated DSI and DSE  
The voltage-gated calcium influx is induced by postsynaptic depolarization.  This 
leads to an increase in intracellular calcium concentration and metabolism of eCBs, 
most likely 2-AG.  2-AG is then released into the synaptic cleft and activates the 
presynaptically located CB1 receptor, and this leads to the suppression of the 
neurotransmitters GABA (DSI; A) and glutamate (DSE; B) (figure taken from 
Hashimotodani et al., 2007b). 
 
A form of eCB release which is receptor driven has also been reported.  The 
activation of metabotropic glutamate and/or acetylcholine receptors have been 
reported to trigger the previously described suppression of excitatory or inhibitory 
inputs (Maejima et al., 2001; Kim et al., 2002).  This has been reported to be 
possible without calcium elevation.  It is thought to be mediated by mGluR type 1 or 
3 and muscarinic acetylcholine receptors type 1 and 3 (M1/M3 receptors) via G-
proteins stimulation of certain PLCβs (Hashimotodani et al., 2007b).  This in turn 
leads to an increase in DAG levels which can be hydrolysed by DAGL to 2-AG.  A 
synergistic mechanism between receptor activation and calcium elevation has also 
been reported and seems to be particularly effective.  While it is possible that the 
two mechanisms work independently, it is thought that both mechanisms act by 




Figure 1.5: Heterosynaptic and homosynaptic regulation of neurotransmitter 
release though eCB signaling  
The model which can be seen above displays the receptor driven eCB release 
dependent and independent of calcium influx into the cell.  This mechanism is 
dependent on PLCβ stimulation by muscarinic acetylcholine receptors (M1/M3) or 
mGluR 1/5.  The effect can be enhanced by an additional increase in the 
intracellular calcium concentration (figure taken from Hashimotodani et al., 2007b). 
 
Using different approaches like the use of DAGL inhibitors or inhibition of 2-AG 
breakdown, 2-AG has been implied to be the relevant eCB in the context of DSE and 
DSI (Chevaleyre and Castillo, 2003; Kim and Alger, 2004; Chevaleyre et al., 2006; 
Hashimotodani et al., 2007a; Uchigashima et al., 2007; Pan et al., 2009).  
Nonetheless, the theory that 2-AG was responsible for retrograde signaling was not 
universally accepted.  In the hippocampus, some groups found that the DAGL 
inhibitor RHC80267 failed to inhibit DSI at inhibitory synapses (Chevaleyre and 
Castillo, 2003; Edwards et al., 2006), while in the cerebellum it had no effect on DSE 
(Safo and Regehr, 2005).  Using another DAGL inhibitor (THL), the role of DAGL in 
hippocampal DSI and cerebellar DSE was demonstrated.  One possible explanation 
for these different findings is the poor selectivity of DAGL inhibitors.  Hopes were 
high for the new DAGL inhibitor OMDM-188 (Ortar et al., 2008), which is more 
active but whose selectivity against a wide range of lipases and other targets has 
yet to be established.  It was shown, that OMDM-188 and RHC-80267 did not affect 
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hippocampal DSI, while THL gave an application dependent result regarding its 
influence on DSI.  All three inhibitors showed that self-inhibition in neocortical 
interneurons was blocked (Min et al., 2010b).  
A plausible explanation for the seemingly contradicting results would be that under 
certain circumstances, eCBs might be stored presynaptically rather than being 
produced on demand (Min et al., 2010a), however there is as yet no direct evidence 
to support this.  Furthermore, OMDM-188 and other DAGL drugs are not able to 
distinguish between the two DAGL isoforms, which makes the recently produced 
DAGLα and β KO mice extremely valuable tools for critically testing their 
requirement for DSI/DSE.  With the help of the KO mice it was shown that DAGLα, 
but not DAGLβ, is required for DSI in hippocampal CA1 neurons (Gao et al., 2010).  
DSE and DSI were also demonstrated to be absent from purkinje cells, and 
interneurons in an independently generated DAGLα KO mouse model while calcium 
levels were comparable to wt mice (Tanimura et al., 2010).  Furthermore, it was 
shown that in the prefrontal cortex, DAGLα (and not DAGLβ) displays a role in 
suppression of inhibitory transmission (Yoshino et al., 2011).  These and other 
experiments suggested 2-AG as the chief eCB involved in synaptic plasticity.  
Anandamide is the other heavily studied eCB, but it is thought to have limited effect 
on altered synapse transmission via retrograde signaling.  Most convincingly 
DSE/DSI were unaltered by changes in FAAH levels, the main anandamide degrading 
enzyme (reviewed in Alger and Kim, 2011).  The DAGLα/β KO mice were thought to 
reveal a final answer to this question, but surprisingly, the DAGLs also displayed a 
considerable influence on basal anandamide levels, even though to a much smaller 
degree than 2-AG (Gao et al., 2010; Tanimura et al., 2010).  A role of anamdamide 
in synapse transmission regulation cannot be ruled out, but the abundant 
pharmacological data points to 2-AG as the main eCB involved in synaptic plasticity 
(Pan et al., 2009; Straiker et al., 2009; Alger and Kim, 2011). 
1.2. Neurogenesis  
The CNS of mammals and advanced vertebrates is complete after the stages of 
developmental neurogenesis.  The brain however displays many forms of plasticity 
to adapt to new environments and situations.  Adult neurogenesis is a form of 
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cellular plasticity and has been first suggested over 50 years ago.  Despite a struggle 
to be widely accepted at first it is now firmly established.  A nice overview about 
the initial findings and the history of neurogenesis research can be found elsewhere 
(Chojnacki et al., 2009).   
In the adult brain, neurogenesis is well documented in the subventricular zone 
(SVZ) of the lateral ventricle and the subgranular zone (SGZ) of the hippocampus 
(Altman, 1962, 1969; Lois and Alvarez-Buylla, 1994).  Adult neurogenesis has been 
linked to learning and memory and disruptions in the process have been related to 
a range of neurodegenerative diseases such as Alzheimer's disease and Parkinson's 
disease. 
1.2.1. Neural stem cells and the adult neurogenic niches 
The SVZ is located in the lateral wall of the ventricle and is the largest and arguably 
the best studied germinal region in mammalian adult brains.  It provides the 
olfactory bulb (OB) with new neurons via the rostral migratory stream (RMS) as well 
as the prefrontal cortex in humans after birth (Sanai et al., 2011). The supply of new 
neurons to the OB appears to be important for some aspects of olfactory function 
(Gheusi et al., 2000; Breton-Provencher et al., 2009).  Furthermore, neuroblasts 
from this area have the ability to migrate to injured brain sites, where they might 
limit damage and/or contribute to the recovery of function (Arvidsson et al., 2002; 
Goings et al., 2004; Zhang et al., 2004).  The importance and functionality of the 
new neurons was critically discussed (Kempermann et al., 2004) and further 
research is needed, but overall it is thought that regulation of adult neurogenesis 
could offer a wide range of therapeutic possibilities.   
The SVZ harbours 4 main cell types which were characterized at the ultrastructural 
level.  These cells are neuroblasts (Type A-cells), SVZ astrocytes (Type B-cells), 
immature precursor cells/transient amplifying cells (Type C-cells) as well as 
ependymal cells (Doetsch et al., 1997).  A layer of ependymal cells separates the 
lateral ventricle and the SVZ, even though occasionally B-cells are in direct contact 
with the ventricle via a single process (Doetsch et al., 1999a).  B-cells can also 
connect to blood vessels via an extension of basal processes.  This enables them to 
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receive signals from the blood and the cerebrospinal fluid (Tavazoie et al., 2008).  In 
this niche, B-cells give rise to the transient amplifying Type C-cells, which 
differentiate into migratory neuroblasts that travel along the RMS to the OB and 
eventually differentiate into neurons (Doetsch et al., 1999b; Doetsch, 2003a).  The 
identity of the true NSC has been discussed excessively and is still debated 
(Chojnacki et al., 2009).  While some arguments were found favouring ependymal 
cells (Johansson et al., 1999) others doubted the neurogenic potential of these cells 
(Capela and Temple, 2002; Spassky et al., 2005).  SVZ astrocytes were suggested as 
an alternative to be the true NSCs (Doetsch, 2003a).  At present, the astrocytic 
marker GFAP (glial fibrillary acidic protein) is often taken as a NSCs marker.  It has 
been argued though, that the expression of GFAP is neither sufficient nor necessary 






Figure 1.6: Schematic representation of neurogenesis in the adult rodent brain 
The adult neurogenic niches, namely the SVZ and the dentate gyrus (DG) of the 
hippocampus hold the adult NSCs.  While the DG provides neurons to the proximity, 
the SVZ provides the OB with new neurons via the RMS.  Once the new cells reach 
the OB they differentiate further.  While moving from the SVZ to the OB, the cells 
mature and the change from the activated stem cell astrocyte stage via the transit 
amplifying cell stage to a neuroblast (figure adapted from Pastrana et al., 2009). 
 
The SGZ is a region within the hippocampus and it is the second key neurogenesis 
site and neurogenesis occurs mainly in locations close to blood vessels (Palmer et 
al., 2000).  In contrast to SVZ neurogenesis, where neurons are born relatively 
distant from the location where they are needed, SGZ neurogenesis occurs in 
proximity to where the new neurons are needed.  In the hippocampus, the newly 
formed neurons have a role in some forms of memory formation such as long term 
spatial memory (Snyder et al., 2005) as well as in cognitive flexibility (Burghardt et 
al., 2012).  Spatial learning influences dendritic arbor formation of new neurons if 
they are functionally integrated into the hippocampus (Lemaire et al., 2012). The 
newly generated neurons are more excitable and more likely to produce a stable 
LTP (Saxe et al., 2006).  This brain area has also been shown to be sensitive to 
damage at early stages of Alzheimer's disease and seem to be entangled with 
neurogenesis, potentially being involved in facilitating the progression of the 
disease, but may also be involved in recovery of functions (Mu and Gage, 2011). 
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1.2.2. Regulation of neurogenesis 
Several aspects of the neurogenic niches contribute to the regulation of 
neurogenesis.  Cell-cell interactions, as well as the contact to the cerebrospinal fluid 
or interactions with blood vessels, help form these complex regulatory 
mechanisms.  Furthermore, the extracellular matrix, as well as the epigenetic state 
of the cells influences the NSCs (Lim and Alvarez-Buylla, 1999; Song et al., 2002).  
Growth factors play a vital role in neurogenesis, and a mitogenic effect on SVZ stem 
cells has been reported, while others contribute to the differentiation mechanisms 
(Panchision and McKay, 2002).  Two of these factors are EGF (epidermal growth 
factor) and FGF-2, which have been shown to have mitogenic activity through 
different mechanisms in the SVZ and furthermore might be involved in cell fate 
decisions (Lennington et al., 2003; Maric et al., 2007).  The FGFR, as well as the 
EGFR (epidermal growth factor receptor), are expressed in the neurogenic niche, 
and SVZ astrocytes express FGFR, whereas EGFR expression was observed in B-cells 
and C-cells (Morshead et al., 1994; Doetsch et al., 2002).  In FGF-2 KO animals, a 
50% reduction of SVZ neurogenesis was observed with a knock on effect on the 
number of new neurons in the OB.  As a result, the OB of these animals is smaller 
when compared to wild type (wt) animals.  A loss of stem cells, rather than 
impaired proliferation causes the reduced stem cell numbers (Zheng et al., 2004).  
In vitro NSCs require growth factors like EGF or FGF-2 to expand.  They can be either 
grown as neurospheres or as adherent cell cultures (Temple, 2001; Conti et al., 
2005).  It should be mentioned that EGF-responsive neurospheres typically arise 
from transit-amplifying C-cells and not in vivo stem cells (Doetsch et al., 2002).  
Therefore, C-cells have stem cell potential in vitro, which is further regulated in 
vivo.  Another set of experiments supports the difference between the two 
signaling mechanisms.  When EGF or the endogenous EGFR ligand tumor growth 
factor (TGF)-α were given via intracerebroventricular infusion an induction of 
mitotically active, functional, radial-glia like cells from progenitor cells was 
observed in the adult SVZ.  This was not observed for FGF-2 (Gregg and Weiss, 
2003).   
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There is a variety of vascular factors affecting the neurogenic niche in the SVZ as 
well as the SGZ.  Endothelial cells are located around the lumen of the blood 
vessels, and the basal lamina separated them from the rest of the brain.  
Neurogenesis often occurs in the proximity of blood vessels (Palmer et al., 2000).  It 
has been reported that co-culture with endothelia cells inhibits NSC cell 
differentiation (Shen et al., 2004).  They secrete many different factors known to be 
mitogenic or to be involved in differentiation or survival such as FGF-2, IGF-1 
(insulin like growth factor 1), vascular endothelial growth factor (VEGF), Platelet 
derived growth factor (PDGF), interleukin 8, and BDNF.  Moreover, they are 
influenced by FGF-2, IGF-1 and TGF-α (reviewed in Doetsch, 2003b).  Noggin, which 
antagonises bone morphogenic protein (BMP) signaling, is produced by ependymal 
cells and inhibits BMP dependent glial differentiation (Lim et al., 2000).  Together 
this illustrates the significant role of vascular factors in neurogenesis. 
Furthermore, neurotransmitter signaling has been linked to adult stem cell niche 
regulation and is discussed elsewhere (Hoglinger et al., 2004; Vaidya et al., 2007; 
Conover and Notti, 2008).  Many regulatory mechanisms are similar between tumor 
stem cells and NSCs and EGF, FGF, Sonic hedgehog homolog (shh) and Notch 
signaling has been demonstrated to be significant for tumour maintenance and 
initiation (Sanai et al., 2005).  This is an additional aspect, which makes it essential 
to understand the regulation of NSCs, as it might be transferrable to cancer stem 
cell research and tumour treatment.   
1.2.3. Changes in neurogenesis in disease  
Several neurodegenerative diseases have been linked to changes in neurogenesis.  
A reduced amount of proliferation is observed in the SVZ leading to a compromised 
olfaction, which is used as an early diagnostic indication for human Parkinson's 
disease cases.  In these patients, the dopaminergic input into the SVZ, which is 
known to have a regulatory role for the stem cell niche is reduced, leading to a 
reduced SVZ neurogenesis.  Therefore, rather than being the cause of Parkinson's 
disease it is a consequence.  However, early treatment of Parkinson's disease 
incorporates an increased exercise regime thought to be beneficial via multiple 
mechanisms including increased neurogenesis (Alonso-Frech et al., 2011). 
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A misregulation of neurogenesis is also observed in Alzheimer's disease.  While 
increased proliferation coupled to an increased expression of immature neuronal 
markers has been reported in the hippocampus (Jin et al., 2004) others have shown 
a decrease in SVZ neurogenesis in Alzheimer's disease patients (Curtis et al., 2007).  
Overall proliferation in the neurogenic niches seems reduced within the CNS in 
Alzheimer's disease animal models (reviewed in Abdipranoto et al., 2008).  
Furthermore, amyloid β plaques, which are closely linked to Alzheimer's disease, 
inhibit human NSC proliferation and differentiation in vitro (Abdipranoto et al., 
2008).  A discussion on a neurogenesis based strategy for therapy or diagnosis can 
be found elsewhere (Mu and Gage, 2011).   
An impaired neurogenesis process has also been shown to have an effect on mood 
and depression.  Studies have shown a connection between low levels of 
neurogenesis and depression (Sapolsky, 2004), while others showed that impaired 
neurogenesis does not automatically lead to depression (Vollmayr et al., 2003).  A 
variety of antidepressants increase neurogenesis in the DG and neurogenesis 
furthermore has been shown to be required for the effect of antidepressants 
(Santarelli et al., 2003).  Others doubt the logic applied in this publication based on 
the used methodology (Phillips et al., 2006).  Therefore, even though changes in 
neurogenesis might not be the direct cause of depression, they might underlie the 
long-term tendency as well as nature for depression to reoccur (Phillips et al., 
2006).  A recent study investigated the effect of antidepressants on human with a 
serious depressive disorder.  They found that hippocampal neural progenitor cells 
and angiogenesis are selectively increased in the mid DG as well as the anterior.  As 
has been seen in other tissues where proliferation occurs, these results point 
potentially towards a relationship between neurogenesis and angiogenesis and 
furthermore might offer a potential insight into the role of theses mechanisms for 




1.2.4. Adult neurogenesis in humans 
As for most biological mechanisms the majority of research on adult neurogenesis is 
performed on animal models such as rodents in combination with in vitro research.  
There is a vast variety of promising results regarding neurogenesis, RMS migration, 
and OB neurons based on rodent research.  The leading question is:  "How similar is 
adult human neurogenesis to that seen in rodents?" 
A study based on 5 human cancer patients provided the first solid evidence for 
adult neurogenesis in humans.  The patient had been given BrdU as part of their 
tumour diagnostic treatment.  Post mortem tissue from these cases showed BrdU 
labelled cells in the SGZ as well as in the SVZ (Eriksson et al., 1998).  The extent and 
relevance of human neurogenesis is discussed until today.  Optimistic views argue 
in favour of a functional, anatomically altered RMS (Curtis et al., 2007; Wang et al., 
2011) and progenitors within the human OB itself (Pagano et al., 2000).  
Interestingly, another migratory stream has been identified in humans targeting the 
prefrontal cortex.  This might fill the need for an increased regional complexity in 
humans compared to animals (Sanai et al., 2011).  A particularly clever way to 
investigate human neurogenesis was used by Bergmann and colleagues based on 
14C released by atom testing in 1963.  Since then 14C levels have steadily declined 
allowing to judge the "age" of a neuron based on its 14C concentration it integrated 
at its birth.  If a neuron has a different "age" from the surrounding cells, this 
indicates, that neurogenesis must have taken place.  Only a limited number of new 
cells were found in the human OB in this study (Bergmann et al., 2012).  While the 
technique is very promising and holds a lot of potential, the choice of patients, the 
relevance of the OB and a good sense of smell in the studied patients is discussed 
critically by the authors (Bergmann et al., 2012; Macklis, 2012).  Results in mice also 
saw considerable death of adult born neurons if the mice were not exposed to new 
smells (Lazarini and Lledo, 2011). This raises the question to whether adult 
neurogenesis in humans might be missed or underestimated due to the failure of 
new neurons to survive.  It would be interesting to use the 14C method to 
investigate other neurogenic brain regions in humans as has been done by Eriksson 
and colleagues (Eriksson et al., 1998).  Therefore, even though the extent of human 
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neurogenesis is still debated, the majority of data point towards at least small 
amounts of neurogenesis in the adult human brain.   
1.2.5. The role of the eCB system in neurogenesis 
The different components of the eCB system are expressed by neural progenitor 
cells and have been suggested to play a prominent role for their proliferation.  
DAGLα is expressed by the ependymal cells lining the lateral ventricle and by cells 
displaying proliferation markers (Goncalves et al., 2008).  It was also found to be 
present in cultured neurospheres and different NSC lines (as well as DAGLβ) where 
it is essential for their proliferation (Molina-Holgado et al., 2007; Goncalves et al., 
2008).  The DAGL inhibitor RHC80267 can suppress the proliferation of cells in the 
SVZ in young mice.  Together these results indicate that the DAGLs are needed for 
NSC proliferation.  Furthermore, RHC as well as THL significantly reduce the number 
of new neurons in the OB, which is due to a lack of neuroblasts migrating through 
the RMS (Goncalves et al., 2008).  Neurogenesis displays dependence on different 
DAGL isoforms in the different brain regions.  In DAGLα KO mice, a 50% reduction in 
proliferating cells was observed in the SVZ in young adult mice, with a similar 
reduction seen in the DG of the hippocampus.  Knocking out DAGLβ however only 
leads to a reduced proliferation in the DG (Gao et al., 2010).  Taken together, these 
results show the importance of DAGL for adult neurogenesis.  
Cells expressing the CB1/2 receptors typically also express DAGL suggesting an 
autocrine signaling mechanism.  It has been demonstrated, that 2-AG can increase 
the number of BrdU positive NSCs, and this occurs in a CB1 receptor dependent 
manner (Aguado et al., 2005).  CB1 and CB2 receptors are expressed by NSC as well 
as in stem cell niches (Aguado et al., 2005; Aguado et al., 2006; Palazuelos et al., 
2006; Goncalves et al., 2008) and are also needed for the proliferation of cultured 
NSCs (Goncalves et al., 2008).  More recently the CB2 receptor has been shown to 
promote neural progenitor proliferation through the mTOR signaling cascade 
(Palazuelos et al., 2011).  Progenitor proliferation and astrogliogenesis are impaired 
in CB1 receptor KO mice further emphasizing the role of the eCB system in 
neurogenesis.  The 2-AG degrading enzyme FAAH is expressed by proliferating adult 
neural progenitor cells and postnatal glial cells as well (Aguado et al., 2005).  
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Increasing eCB levels by using FAAH inhibitors can also stimulate neural progenitor 
proliferation in CB1 receptor deficient mice (Aguado et al., 2006).  A similar result 
has been seen using a neurosphere assay, where CB1 and/or CB2 receptor 
activation increases progenitor proliferation.  This effect is mirrored by the use of 
FAAH inhibition, leading to an increase of eCBs (Aguado et al., 2005; Palazuelos et 
al., 2006; Molina-Holgado et al., 2007).  Inhibition of CB1 or CB2 receptors ,on the 
other hand, decreases NSC proliferation, while it has no effect on their survival 
(Goncalves et al., 2008).  This overall shows the role of CB1 and CB2 receptors in 
progenitor proliferation. 
Surprisingly, CB2 receptor antagonism, but not CB1 receptor antagonism is 
associated with a reduction in neurogenesis in the SVZ of young adult mice.  This 
has also been seen for the DAGL inhibitor, and a substantial reduction in neuroblast 
numbers migrating through the RMS was observed.  To test if agonism can increase 
neurogenesis, a CB1/2 receptor agonist, or CB2 receptor agonists were used to 
treat young animals, but only a very modest increase of neurogenesis was 
observed.  This might reflect that at a young age, eCB dependent neurogenesis 
might be occurring at a near optimal level and cannot be increased much further.  
However, in older animals where neurogenesis is dramatically reduced, it was 
possible to increase neurogenesis substantially with CB2 receptor agonists or FAAH 
inhibitors (Goncalves et al., 2008), suggesting that the age-related decline might 
reflect a run-down in eCB signaling.  
1.2.5.1. The role of the eCB system in neuronal migration and  
  integration 
After the generation of new neuroblasts in the lateral wall of the ventricle, these 
cells have to migrate to the correct location and differentiate into mature neurons.  
Recently, the eCB system has also been shown to play a prominent role in 
neuroblast migration in the RMS of young adult animals (Oudin et al., 2011a).  
Previously, their role in other migratory events has been shown in the context of 
tumour cell migration (Hermanson and Marnett, 2011).  The newly found role in 
neuroblasts migration is especially intriguing, since these cells have been reported 
to migrate to regions of injury and therefore could be important for brain repair.  
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Mouse migratory neuroblasts express DAGL as well as MAGL.  In a cell based 
migration assay, DAGL inhibition, as well as CB1/2 receptor inhibition decreased 
migration.  Additionally the eCB system in vivo has a role in morphology changes, 
which are associated with migration like nucleokinesis or process branching (Oudin 
et al., 2011b).  This indicates that the DAGL-eCB system is involved in neuroblast 
migration.  As mentioned above, CB2 receptor agonist treatment not only increased 
SVZ proliferation, but also increased the generation of new neurons in the OB, two 
weeks after treatment (Goncalves et al., 2008).  Therefore, eCBs also have a role in 
the integration of new neurons.   
1.2.5.2. eCB requirement for neurogenesis changes with age 
Neurogenesis in the SVZ drastically decreases between month 2 to 22 in mice (Luo 
et al., 2006) and a similar reduction in neurogenesis with age has been observed 
with humans (Knoth et al., 2010).  Comparing 6 week old mice with 6 month old 
mice, the neurogenesis levels in the SVZ dropped by ~80% and was almost not 
existent by 20 month (Goncalves et al., 2008).  6 month old mice showed increased 
cell proliferation by approximately 3.5 fold in the SVZ after CB2 receptor agonist 
treatment, but not CB1 receptor agonist treatment.  This effect can be prevented 
by the use of a CB2 receptor antagonist.  The increased proliferation was linked to 
an increased number of new neurons in the OB 2 weeks later (Goncalves et al., 
2008).  The CB1/CB2 receptor agonists Win-55,212-2 displayed a similar effect to 
the CB2 receptor agonist, as it increased proliferation by 3.5-fold and was 
prevented by a CB2 receptor antagonist.  FAAH KO can induce hippocampal 
progenitor proliferation (Aguado et al., 2005) and blocking eCB degradation by 
inhibiting FAAH with URB597 resulted in a similar CB2 receptor dependent increase 
in proliferation (Goncalves et al., 2008).  To test if the effect was even bigger in 
older mice, 20 month old mice were tested and display a 6-fold proliferation 
increase.  This retuned them to the neurogenesis levels of a 6-month old mouse 
(Goncalves et al., 2008).  These experiments display the eCB dependency of 
neurogenesis especially in old age and furthermore environmental factors such as 
high fat diet have been demonstrated to influence eCB dependent neurogenesis.  
The CB1 receptor antagonist AM251 can alter the proliferation in mice, which are 
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fed a high fat diet.  This has different effects on different brain regions.  In the SVZ a 
decrease of BrdU positive cells was found, while an increase was identified in the 
SGZ (Rivera et al., 2011).  Therefore, the effect of eCB signaling on neurogenesis 
might be limited to some life conditions and stages.   
1.3. The therapeutic potential of the eCB system  
The eCB system has many roles within the CNS and beyond and its misregulation is 
involved in a range of diseases.  Moreover, certain symptoms such as pain can be 
addressed via modulation of eCB signaling.  Therefore, it is not surprising that the 
eCB system provides a promising target for therapeutic purposes and indeed 
several drugs are now in clinical trials.  The many medicinal effects of cannabis 
sativa on the human body and mind have been known since it was described 2700 
BC, but it took until the 20th century to start understanding the underlying 
mechanism.  The increased understanding of the relationship between the eCB 
system and diseases allows us to design new treatment strategies as well as 
develop new drugs.   
Here, we will focus on the role of the eCB system in obesity and neuroprotection, 
but further connections between the eCB system and diseases have been made in 
the area of anxiety and depression, pain and inflammation as well as liver disease 
and osteoporosis (Di Marzo, 2008; Fowler et al., 2010).  In many cases, it has been 
shown that the eCB system can have enhancing as well as reducing effects on 
symptoms, which displays the complexity of the system.   
1.3.1. Eating disorders and obesity 
Considering the well established appetite increasing effect of cannabis it is not 
surprising that eating disorders are on the list of diseases to be potentially 
addressed by targeting the eCB system.  Alterations in eCB levels might be an 
adaptive response to encourage eating or to deal with the lack of food.  It 
furthermore was linked to a change in appetite causing overeating which in turn 
results in fat accumulation and/or obesity (reviewed in Di Marzo 2008).  The eCBs 
regulate appetite though their pro-orexiogenic mechanisms in the hypothalamus.  
Adipocytes release leptin which leads to a reduction of 2-AG as well as anandamide 
levels (Di Marzo, 2008).   
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Some results point to adult neurogenesis occurring in the hypothalamus and 
moreover it might causally influence the regulation of energy balance (Kokoeva et 
al., 2005).  This is interesting because a connection between diet induced obesity 
and CB1 receptor dependent regulation of proliferation has been recently reported.  
This observation provides support for the notion that neurogenesis is regulated via 
CB1 receptor signaling as a response to obesity (Rivera et al., 2011).  Mice were fed 
a low or high fat diet and treated with AM251.  AM251 changed food intake and 
weight in either case but interestingly only in the animals receiving a high fat diet 
showed an effect on proliferation.  This might indicate that the observed 
proliferation is not dependent on caloric intake but on the type of nutrient (Cota 
and Marsicano, 2011; Rivera et al., 2011). 
A change in hippocampal eCB signaling also has been observed in diet-induced 
obese mice.  eCB-mediated synaptic plasticity was especially affected within the 
CA1 region.  Here, an enhancement of long-term depression of inhibitory synapses 
and DSI was observed (Westbrook et al., 2008).  Food availability can change the 
output of the hypothalamic nuclei, which underlies energy homeostasis.  GABA 
synapses in the dorsomedial hypothalamus, a part of the brain known to be 
involved in satiety signals, display eCB dependant LTD and were the focus of this 
study.  24h of food deprivation causes a loss of CB1 receptor signaling resulting in 
the synapses only being capable of LTP, but not LTD.  Therefore, the regulation of 
CB1 receptor signaling can act as a switch between LTD and LTP at GABAergic 
synapses (Crosby et al., 2011).  
In summary, the eCB system was shown to react as well as act upon energy level 
changes and is an excellent target to address eating disorders.  It has been shown 
that CB1 receptor agonist treatment in low doses increases food uptake, while CB1 
receptor antagonist decreases food uptake as well as body weight (Mackie, 2006).  
This has been exploited by developing CB1 receptor antagonists as novel drugs 
against obesity such as rimonabant and taranabant (Di Marzo, 2008). 
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1.3.2. Neuroprotective effects of eCB signaling  
The eCB system is involved in providing neuroprotection following neuronal 
damage.  This damage can be either acute, like trauma or ischemia, or chronic as 
caused ,for example, by Alzheimer's disease (Fowler et al., 2010).  It has been 
demonstrated that 2-AG levels are significantly increased following close head 
injury in mice.  Mice treated with synthetic 2-AG after head injury displayed 
reduced brain oedema, an improved clinical recovery, a decreased infarct volume 
as well as decreased hippocampal cell death.  The positive effect of 2-AG could be 
reduced in a dose dependent manner with the use of CB1 receptor antagonist SR-
141761A (Panikashvili et al., 2001).  A neuroprotective effect was also observed 
when CB1 receptor agonists were used in a multiple sclerosis model (Croxford et al., 
2008).  CB1 receptor KO mice helped to support the notion of the protective effects 
of CBs, as CB1 receptor KO mice showed more severe symptoms after a stroke.  
They died more frequently from focal cerebral ischemia, and the infarct size was 
increased amongst other symptoms.  This indicates that the CB1 receptor 
dependent eCB pathway protects the mouse brain against at least some aspects of 
stroke (Parmentier-Batteur et al., 2002).  Furthermore, CB1 receptor KO mice 
recovered more slowly from close head injury compared to wt mice (Panikashvili et 
al., 2005).  These and other results demonstrate that the eCB can have a 
neuroprotective effect and together with other aspects of eCB signaling, have 
raised hope in the context of different neurodegenerative diseases such as 
Alzheimer's disease or multiple sclerosis (Fowler et al., 2010; Karl et al., 2012; Pryce 
and Baker, 2012).  However, the inverse CB1 receptor agonist rimonabant also has 
been demonstrated to have neuroprotective properties in some animal models 
(Fowler et al., 2010), which indicates that in some context eCB mediated 
mechanisms can have a neurotoxic effect as well.  Therefore, further research is 





1.4. Aims and objectives 
At the start of my project, our lab was strongly involved in researching the role of 
eCB signaling in adult neurogenesis in the SVZ as well as NSC proliferation 
(Goncalves et al., 2008).  This went hand in hand with an interest in the 
involvement of eCB signaling in RMS migration (Oudin et al., 2011b).  Since cloning 
the DAGLs in 2003 (Bisogno et al., 2003) our lab was particularly interested in DAGL 
depended eCB signaling.  Very little information is available on what is driving the 
eCB system in NSCs and possible mechanisms for DAGLα regulation (discussed in 
Reisenberg et al., 2012 ).   
As the brain is a highly heterogeneous tissue, it is extremely challenging to uncover 
molecular mechanisms in vivo.  The Cor-1 cells are a NSC model (Conti et al., 2005) 
and were used as an in vitro model for our proliferation and migration studies.  Cell 
proliferation, migration, and differentiation are the key processes occurring during 
neurogenesis as well as during neural development and relevance for the eCB 
system was identified for the first two steps.  Moreover, the Cor-1 cells express the 
core components of the eCB signaling machinery and require basal eCB tone for 
proliferation and migration (Goncalves et al., 2008; Oudin et al., 2011b).  Therefore, 
they are a suitable model system to investigate eCB signaling in NSCs.   
We wanted to address the following questions: 
 Does eCB signaling regulate the differentiation of Cor-1 cells to neurons 
or glia? 
 What drives eCB signaling in NSCs and what are the downstream 
effectors?  
 Do DAGLα levels change during the differentiation of Cor-1 cells into 
neurons or glia? 
 Can we establish an assay to analyse DAGL activity? 
 Is DAGL regulated by post translational modified such as ubiquitination 
or phosphorylation?  
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CHAPTER II: Material and Methods 
1. Materials and Methods 
2. dkajdl 
2.1. Materials 
All reagents were purchased by Sigma-Aldrich or VWR unless otherwise stated. 
Cor-1 cell lines 
Cor-1 cells are ES cell derived mouse NSCs and were a kind gift from Austin Smith 
(Conti et al., 2005).   
Cor-1 cells were transfected with plasmids (pCDNA3.1D/V5-His-TOPO) containing 
the human DAGLα or mouse DAGLβ gene (plasmids Praveen Paul and Fiona Howell) 
and stable cell lines were established and named V5α7 and V5β5 respectively 
(Philipp Sütterlin).   
A stable Cor-1 cell line expressing the human DAGLα in pcDNA3.1D/V5-His-TOPO 
vector with mutations in the putative destruction (d-) box motive were established 
for this study.  The amino acid sequence was changed from 892R-G-E-L-A-L-H-N-G to 
892A-G-E-A-A-L-H-N-G and the mutations of the putative d-box were carried out and 
confirmed by Exonbio.  A stable cell line was established expressing the d-box 
mutated DAGLα-V5 construct and named Mα8. 
Phosphate buffered saline (PBS) 
One tabled (Oxoid) containing 0.20g/l KCl, 0.20g/l KH2PO4, 8g/l NaCl, 1.15g/l 
Na2HPO4 dissolved in 100ml distilled water  
LB media and LB agar 
25g Luria bertani (LB) broth powder (Merck) or 37g LB agar powder (Merck) was 
added to 1l of water and autoclaved.  50µg/ml ampicillin was added if required. 
PBST 
PBS plus 0.1% Tween20 
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Tris buffered saline (TBS) 
3.029g Tris (hydroxymethyl)-methylamine (BDH) and 4.383g NaCl (BDH) dissolved in 
500ml distilled water and adjusted to pH 7.4 
TBST 
TBS and 0.1% Tween20 
Lysis buffer (ODG for Cor-1 cells) 
50mM TRIS pH8, 150mM NaCl, 10mM MgCl2, 1% triton-X, 5% glycerol, 10mM NaF, 
1mM sodium orthovanadate, 1mM PMSF and complete protease inhibitors (Roche).   
Lysis buffer (brain tissue) 
50mM Tris pH7.5, 150mM NaCl, 1% triton-X, 10mM NaF, 1mM sodium 
orthovanadate, 1mM PMSF and complete protease inhibitors (Roche).   
Lysis buffer for membrane extraction (DAGL activity assay) 
20mM HEPES (pH 7), 2mM DTT, 25M Sucrose, protease inhibitor, 10mM NaF, 10nM 
NaVO3 
Membrane buffer (DAGL activity assay) 
20mM HEPES (pH 7), 2mM DTT, protease inhibitor, 10mM NaF, 10nM NaVO3 
5x Protein loading buffer 








Table 2.1: SDS-polyacrylamide gel 
 7.5% running gel 5% stacking gel 
30% acryl amide/Bis (VWR 
international) 
2.5ml 1.67ml 
1.5M Tris, pH 8.8 (VWR 
international) 
3.7ml 1.25ml 
10% SDS (VWR international) 100ul 100ul 
H2O 3.63ml 6.91 ml 
TEMED (National diagnostics) 6.6ul 20ul 




Table 2.2 Buffers for western blot analysis 
 10x running buffer 10x transfer buffer 
Tris Base 30.3 g 30.3 g 
Glycine 144.2 g 144.2 g 
SDS 10 g - 
Methanol - 200 ml 
made up to 1 L with distilled H2O 
 
Fixative for immunocytochemistry 




Blocking and permeabilising buffer for immunocytochemistry 
PBS with 0.1% Troton-X-100, 1%BSA and 0.1% Na azide 
Table 2.3: Primary antibodies for western blotting  
Antibody Dilution Species Company 
Anti-V5  1:1000 - 1:5000 Mouse Invitrogen 
GFAP 1:20000 Rabbit Dako 
Tuj-1  1:500 Mouse Abcam 
Tuj-1 1:500 Rabbit Covance 
Anti-V5  1:3.000 Rabbit Invitrogen 
Nestin 1:20 Mouse DSHB 
DAGLα 1:1000 Rabbit Gift from 
Watanabe 
DAGLα 1:1000 Guinea pig Gift from 
Watanabe 
DAGLβ 1:500 Rabbit Eurogentech 
CB1 receptor 1:1000 Rabbit Gift from 
K.Mackie 
Ubiquitin 1:250 Mouse Stressgen 
Ubiquitin 1:2000 Rabbit Abcam 
p70 S6 kinase 1:1000 Rabbit Cell signaling 
Phospho P70 S6 
kinase 
1:1000 Rabbit Cell signaling 
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Sox2 1:1500 Rabbit Chemicon 
Actin 1:5000 Mouse Abcam 
InsR β 1:100 Mouse Abcam 
FAAH 1:1000 Mouse Abcam 
*affinity purified against the SSDSPLDSPTKYPLT epitope of DAGLβ 
Table 2.4: Secondary Antibodies for western Blotting  
Antibody Dilution Species Company 
Anti-mouse HRP  1:3000 Horse Vector Laboratories 
Anti-goat HRP 1:3000 Horse Vector Laboratories 
Anti-rabbit HRP  1:3000 Horse Vector Laboratories 
Anti-mouse Alexa Fluor 700 1:3000 Goat Invitrogen 
Anti-rabbit Alexa Fluor 800 1:3000 Goat Invitrogen 
 
Table 2.5: Primary Antibodies for immunofluorescence  
Antibody/Dye Dilution Species Company 
Anti-V5  1:500  Mouse Invitrogen 
GFAP 1:2000 Rabbit Dako 
Tuj-1  1:500 Mouse Abcam 
Tuj-1 1:500 Rabbit Covance 
Anti-V5  1:3.000 Rabbit Invitrogen 
Nestin 1:20 Mouse DSHB 
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DAGLα 1:500 Rabbit Gift from 
Watanabe 
DAGLα 1:500 Guinea pig Gift from 
Watanabe 
CB1 receptor 1:100  Rabbit Gift from 
K.Mackie 
InsR 1:200 Rabbit Santa Cruz 
InsRβ 1:50 Mouse Abcam 
IGF-1 1:100 Rabbit Abcam 
Phalloidin 
AlexaFluor 488 




1:10.000   Invitrogen 
 
Table 2.6: Secondary Antibodies for immunofluorescence 
Antibody Dilution Species Company 
Anti-mouse IgG Alexa594  1:1000 Goat Molecular probes 
Anti-rabbit IgG Alexa594  1:1000 Goat Molecular probes 
Anti-guinea pig Alexa594 1:1000 Goat Molecular probes 
Anti-mouse IgG Alexa488  1:1000 Goat Molecular probes 






Table 2.7: Drugs used on Cor-1 cells 
Drug Target Concentrations 
used  
Company 
ACEA CB1 receptor agonist 0-1µM Tocris 
AG1024 IGFR 




AG1478 EGFR inhibitor 500nM Biomol 
AM251 CB1 receptor antagonist 0-1µM Tocris 
AM630 CB2 antagonist 0-1µM Tocris 
Go6976 PKC inhibitor 0-1µM Tocris 
H-1356 IGFR inhibitor 0-1µM Bachem 
JTE-907 CB2 receptor antagonist 0-1µM Tocris 
JWH-133 CB2 receptor antagonist 0-1µM Tocris 
KN62 CaM kinase inhibitor 0-1µM Tocris 
Lacatcystin Proteasome inhibitor 0-0.5µM Sigma 
LY320135 CB1 antagonist 0-1µM Tocris 
OMDM-188 DAGL inhibitor 0-1µM Kind gift from the 
DiMarzo lab 
PD173074 FGFR inhibitor 500nM Calbiochem  
(Merck) 
PD168393 EGFR inhibitor 0-500 nM Calbiochem  
(Merck) 
Rapamycin mTOR inhibitor 0-2µM Sigma 
Roscovitine CDK1,2,5 kinase 0-10µM Cell signaling 
 
Mowiol mounting solution 




1mM EDTA filter sterilised, 1% chick serum, 0.025% trypsin (Invitrogen) 
Table 2.8: In-house N2 
In-house 
preparation 


























2.2.1. Cell culture  
Passaging 
Cor-1 cells were grown at 8% CO2 and 37°C in growth media in T75 tissue culture 
flasks or 10cm dishes (Nunc) coated with 0.1% gelatine in PBS for 15 min to prevent 
neurosphere formation.  For passaging, Cor-1 cells were trypsinised for <1 min with 
1ml trypsin, washed off and collected in 9ml growth media, spun down at 240 g for 
3min, before finally being resuspended in fresh growth media.  
Cells used were from passage 25-40 and only used for experiments when 
morphology and proliferation rate appeared normal. 
Cor-1 growth media 
NS-A media (Cadama) supplemented with N2 (Invitrogen) or in house N2, L-





Cor-1 seeding for immunocytochemistry 
For the immunocytochemistry experiments, 13mm glass cover slips in individual 
wells of 4-well culture dishes (Nunc) were coated with 500µl 0.1% gelatine solution 
and left for at least 15min at RT.  The gelatine was removed before adding Cor-1 
cells in growth medium typically at concentrations between 5,000-20,000 
cells/well.  Cells were incubated at 37oC, in an 8% CO2 incubator until they reach the 
desired level of confluence.  
Cor-1 seeding for 96-well experiments 
96-well plates (Nunc) were coated with 100µl 0.1% gelatine solution and left for 
15min at RT.  The gelatine was removed and Cor-1 cells were seeded between 
3,000-10,000 cells/well and grown at 37°C in 8% C02.  Drugs were typically added 
the next day in a small volume of media. 
Freezing of Cor-1 cells 
Cells were frozen down in 500µl growth media and 10%DMSO (dimethyl sulfoxide) 
in 1.8ml cryotubes (Nunc) as cell pellets.  Cells were recovered by being grown in 
preheated growth media in gelatine coated 10cm dishes overnight.  The next day, 
the media was replaced by fresh media to remove DMSO residuals. 
2.2.2. Differentiation of Cor-1 cells 
2.2.2.1. Neuronal differentiation 
Plating of Cor-1 cells for experiments 
Glass cover slips in 4-well culture plates (immunocytochemistry), 96-well plates, or 
6-well dishes (western blotting) were coated with a 50μg/ml solution of Poly-L-
ornithine (Sigma) and incubated overnight at 4°C.  The next day the plates or dishes 
were washed three times with sterile water, and a 6μg/ml solution of laminin 
(Sigma) was added and incubated for at least 2h at 37°C in a humidified incubator.  





Neuronal cell culture 
Cells were seeded at a concentration between 5,000 to 20,000 cells/well 
(coverslips) or 3,000 to 10,000 cells/well (96-well plates) or 100,000-500,000 (6-well 
plate) depending on the experiment in growth media and incubated overnight.  The 
next day media was changed to the neuronal differentiation media.   
Neuronal differentiation media 
For neuronal differentiation NS-A media was supplemented with 2mM l-glutamine, 
N2, 5ng/ml FGF-2 and B27 at the concentration recommended by the supplier 
(Invitrogen).  This media is referred to as neuronal differentiation media in the 
remainder of this report.  Half the media volume was typically replaced at 2 or 4d 
for immunocytochemistry or after 2d for western blot analysis samples.  
2.2.2.2. Astrocyte differentiation 
Plating of Cor-1 cells for experiments 
Cover slips/ 96-well plates/6-well dishes were coated with 0.1% gelatine and cells 
were seeded at a concentration between 5,000 and 500,000 cells/well in growth 
media depending on the experiment and incubated overnight.  The next day, the 
media was changed to astrocytic differentiation media and the cells were 
differentiated between 1-7 days depending on the experiment. 
Astrocytic differentiation media 
For astrocytic differentiation NS-A media was supplemented with 1ng/ml BMP-4 
(R&D systems).  This media is referred to as astrocytic differentiation media in the 
remainder of this report.  Alternatively 5% fetal bovine serum was used to 
differentiate the cells to astrocytes.  
2.2.3. Cell proliferation assay 
Time-lapse microscopy (IncuCyteTM imaging) 
Cor-1 cells were grown in 96-well plates (Nunc) coated with gelatine in growth 
media and left to attach over night.  Drugs were diluted in growth media and added 
to the 96-well plates the following day, and pictures were taken of cells while they 
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were still growing under incubation conditions using IncuCyteTM imaging for 24-48h.  
The integrated confluence metric from IncucyteTM is used as a surrogate for cell 
number (For further information see: 
http://essenbioscience.com/IMAGES/proliferationappnote.pdf).  The growth rate 
over time was established by comparing the area under the curve, which was 
calculated using an Excel macro. 
2.2.4. Derivation of clonal, transgenic cell lines 
Transformation 
1-5μg DNA was added to 50μl chemically competent Escherichia coli (E.Coli) DH5α 
cells (Invitrogen) and incubated on ice for 30min. Cells were heat shocked for 20sec 
in a 37°C water bath and incubated on ice for 2min. 900μl LB media was then added 
and the cells shaken at 37ºC for 1h at 6g before being spread onto ampicillin agar 
plates.  
The High Speed Purification Protocol from Qiagen was used following the 
manufacturer’s protocol.  
Nucleofection 
Nucleofection is a transfection method, which allows the efficient and reproducible 
transfer DNA and RNA into cells.  The method is electroporation based and uses a 
device (Nucleofector), which offers optimized electronical parameters.  In 
combination with cell specific reagents it is possible to transfer DNA and RNA 
directly into the nucleus and cytoplasm.  Thus, it offers an excellent alternative to 
viral vectors to transfect even non-dividing cells.  The Nucleofection Technology 
was invented by the Amaxa AG.  
6-well plates were prepared by coating with 0.1% gelatine in PBS for 15min, adding 
growth medium and preheating in a 37°C incubator.  2µg of plasmid DNA are 
required, and 1-5 million cells are needed per nucleofection.  The Cor-1 cells were 
harvested and centrifuged as has been done for the cell passaging, all traces of 
medium were removed before cells were resuspended in nucleofection solution V 
(Amaxa biosystems) (100µl/nucleofection).  100µl nucleofection solution with 
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resuspended cells and the appropriate plasmid amount was added to a cuvette.  
Nucleofection was performed using a Nucleofector II machine (Amaxa biosystems) 
on programme T-030.  To increase survival cells were transferred into medium 
containing 10% serum for 5min and added to the previously prepared medium in 
the 6-well-plate. 
Selection with G418 
After nucleofection cells were grown on 0.1% gelatine coated 6-well plates for 2d in 
growth media before the growth media was supplemented with 400µg/ml G418.  
Media was then exchanged daily to remove cell debris, and the antibiotic selection 
was maintained until individual colonies were visible by eye.  About 10d after the 
nucleofection colonies were picked and transferred onto gelatine coated 24-well 
plates where they were grown until 70% confluent, which means that they are 
ready to be transferred to 6-well plates.  Finally, the cells are transferred to T75 
tissue culture flasks and further expanded.  
Cell lines were maintained in media containing 300µg/ml G418 and screened for 
successful insertion of the mutated DAGLα-V5 construct by western blotting and 
immunocytochemistry. 
2.2.5. Immunocytochemistry 
The Cor-1 cells were grown on glass cover slips suitably coated for the experiment 
(see above for details). 
Cell fixation 
The cells were fixed by adding equal amounts of 4% PFA (Sigma) and 10% sucrose 
typically after 24-48h to the growth media.  After 20min, the medium was replaced 
with 500μl of the same fixative (4% PFA, 10% sucrose) straight onto the cells for 
20min.  Cover slips were then washed three times for 5min in PBS.  
Antibody/ dye 
Cover slips were incubated with 350μl blocking and permeabilising buffer for 1h at 
room temperature (RT) in order to permeabilize the fixed cells and prevent non-
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specific antibody binding.  The primary antibodies were made up in the same 
solution (250μl/well) and added to the cells at 4oC overnight or 1h at RT.  After 
three washes in PBS the secondary antibody solution and Hoechst, also made up in 
blocking buffer, was added for 1h at RT while cover slips were protected from light.  
Following a final three washes in PBS, the cover slips were mounted on slides using 
mowiol (Sigma) and stored in a dark box at 4oC.   
Imaging 
Unless otherwise stated, immunocytochemistry pictures were taken on an 
Axiovision Apotome microscope. 
2.2.6. Immunoprecipitation 
Cells were grown overnight in expansion media, or 3d in differentiation media, in 
10cm dishes.  Cells were lysed as described below, 500µg protein and 2µg anti-V5 
antibody were rotated at 4oC overnight. 
To prepare the beads, 10mg protein A sepharose (Sigma) was added in 200µl cold 
PBS per immunoprecipitation (IP) and rotated at 4oC for 5min.  The protein A 
sepharose beads were centrifuged at 11,000g, wash with 500µl cold PBS three 
times, and resuspended in 500µl lysis buffer.  The beads were added to the lysate 
and rotate at 4°C for 1h and afterwards centrifuged at 11,000g.  The protein A 
sepharose beads with protein were washed three times with 500µl cold lysis buffer.  
50µl 2 x protein loading buffer (dilute with water from 5 x buffer) was added to the 
beads and boiled for 5min and centrifuged for 1min. 20µl supernatant was loaded 
on a SDS-poly-acrylamide gel to separated proteins and later on transfer onto 
nitrocellulose membranes.  Samples were typically loaded with a lysate and a no 
antibody, "negative IP," as controls. 
2.2.7. Western blotting 
Cell lysis 
Cells were cultured in 6-well-plates or 10cm dishes until reaching 70–80% 
confluence, washed in ice-cold PBS and lysed in 50-500μl lysis buffer.  The lysate 
was collected in 1.5ml eppendorf tubes and left to rotate for 1h at 4oC followed by 
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centrifugation at 11,000g for 10min at 4oC to separate out cell debris.  The 
supernatant was collected and stored at -20°C. 
Protein concentration was typically measured with Pierce Protein Assay Kit 
following the manufacturer’s protocol to ensure even protein loading for western 
blotting and calculate the required protein amount for the IPs. 
SDS-PAGE 
15-60µl sample in 5x protein loading buffer were separated on SDS-polyacrylamide 
gels at 120V for approximately 1.5h in running buffer.  Next the samples were 
transferred to nitrocellulose membranes (Amersham) (100V for 60min) in transfer 
buffer. 
Western Blot 
The membrane was blocked in TBS and 5% milk at RT for 1h, and the primary 
antibody solution was applied overnight at 4oC or for 1h at RT.  Next the membrane 
was washed 3 times in TBST for 10min and then incubated with secondary antibody 
solution at RT for 1h.  The secondary antibody was chosen according to 
development method and suitable for the used primary antibody.  After another 
three 10min washes in TBST, the blot was developed using Amersham Enhanced 
Chemiluminescence (ECL) reagents and exposed to X-ray film for HRP labelled 
secondary antibodies.  For Alexa Fluor 700 or 800 labelled secondary antibodies 
Odyssey infra red imaging were used.  Blots were stripped using Re-Blot Plus 
(Chemicon International) if required according to the manufacturer's guidance. 
Quantification 
ECL/ECL plus visualized western blots were scanned in at 2400dpi using a 
PerfectionV700 scanner (Epson) and quantified using ImageJ analysis software.  In 
general, samples were loaded with an equal protein loading where possible and the 
protein of interest was normalised to an actin control. 
Western blots, which were visualised using Odyssey infrared imaging, were 
quantified using the Odyssey software. 
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2.2.8. A surrogate substrate DAGL activity assay 
The following protocol is a modification of the protocols described by Pedicord et al 
2011.  
2.2.8.1. Membrane based DAGL activity assay 
Membrane extraction  
Cor-1 cells were grown up in 10cm dishes or in 6-well plates until ~70% confluent.  
The cells were washed with ice cold PBS and resuspended in 500µl lysis buffer for 
membrane assay and homogenized with an electric, handheld homogenizer 
(Polytron PT1200 E) (3 times 7sec with 10sec breaks).  The cell lysates were 
centrifuged at 100,000g for 30min at 4°C using an ultra centrifuge.  Afterwards, the 
membrane pellets were resuspended in 250µl membrane buffer and homogenized 
with an electric homogenizer (3 times 7sec with 10sec breaks).  Where possible the 
whole protocol was carried out on ice.   
Coomassie (Bradford) Protein assay (Thermo Scientific) 
A Bradford protein assay was carried out with each sample being tested at 5 
different dilutions (3x) to ensure that the protein concentration lay within the linear 
range of the BSA standard curve.  For further details see the protocol provided by 
the manufacturer.   
DAGL activity assay using the chromogenic substrate PNP 
A 96-well assay using the surrogate substrate 4-nitrophenol butyrate (Sigma-
Aldrich) (PNP) was established.  50mM HEPES pH 7.5 was used as an assay buffer.  A 
minimum of 3 wells were used per condition, and the mean is presented.  Due to 
solubility problems, PNP was pre-diluted in DMSO (5% final concentration) and 
used at 250µM unless otherwise stated.  Membranes were typically used at 
12.5µg/ml FAC, and THL was used as a background control at a concentration of 
1µM to inhibit DAGL activity and added to the membranes 5-10min before the 
substrate was added to half of the plate.  The reactions were measured kinetically 
using the SpectramaxPlus (Molecular Devices) set at 400nm every 12sec for 10min.  
Using the Soft Max Pro software the reaction rate was calculated based on the 
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linear regression and it reflects how much of the surrogate substrate has been 
metabolised. 
DAGL activity assay using the fluorogenic substrate DiFMU 
A 96-well-assay using the surrogate substrate 6, 8-difluoro-4-methylumbelliferyl-
octanoate (DiFMU) (Invitrogen) (PNP) was established.  50mM MES pH6.5 was used 
as an assay buffer and a minimum of 3 wells were used per condition.  For 
consistency reasons DiFMU was pre-diluted in DMSO (5% final concentration) and 
used at 10µM unless otherwise stated.  Membranes were typically used at 
12.5µg/ml FAC and THL was used as a control at a concentration of 1µM to inhibit 
DAGL activity and added to the membranes 5-10 min before the substrate was 
added to half of the plate.  The reactions were measured kinetically using the 
Flexstation (Molecular Devices) set at an excitation wavelength of 360nm and an 
emission wavelength set to 450nm, and the reaction was measured every 10 
seconds for 10min.  Using the Soft Max Pro software the reaction rate was 
calculated based on the linear regression of the first 10 min and reflects how much 
of the surrogate substrate has been metabolised.  Typically the mean of 3-4 wells is 
presented. 
2.2.8.2. Cell based DAGL activity assay 
DAGL activity assay using the chromogenic substrate PNP 
40,000 Cor-1 cells were seeded into 96-well plates and left overnight to attach.  The 
growth media was carefully removed immediately before the assay was taken out 
and replaced with the adequate assay buffer (50mM HEPES pH 7.5).  A minimum of 
4 wells were used per condition and the mean is presented.  Due to solubility 
problems PNP was pre-diluted in DMSO (5% final concentration) and used at 
250µM unless otherwise stated and THL was used as a control at a concentration of 
25µM to inhibit DAGL activity unless otherwise stated and added to the cells 5-10 
min before the substrate was added to half of the plate.  The reactions were 
measured kinetically using the SpectramaxPlus (Molecular Devices) set at 400nm 
and the reaction was measured every 12 seconds for 10 min.  Using the Soft Max 
Pro software the reaction rate was calculated based on the linear regression and 
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reflects how much of the surrogate substrate has been metabolised.  Typically the 
mean of 4 wells is presented. 
DAGL activity assay using the fluorogenic substrate DiFMU 
40,000 Cor-1 cells were seeded into 96-well plates and left overnight to attach and 
the growth media was carefully removed immediately before the assay was 
performed and replaced with the adequate assay buffer (50mM MES pH 6.5).  A 
minimum of 4 wells were used per condition and the mean is presented.  For 
consistency reasons DiFMU was pre-diluted in DMSO (5% final concentration) and 
used at 10µM unless otherwise stated.  The membranes were typically used at 
12.5µg/ml FAC (final assay concentration) and THL was used as a control at a 
concentration of 25µM to inhibit DAGL activity unless otherwise stated and added 
to half of the cells 5-10 min before the substrate was added.  The reactions were 
measured kinetically using the Flexstation set at an excitation wavelength of 360nm 
and an emission wavelength set to 450nm and measured every 10sec for 10min.  
Using the Soft Max Pro software the reaction rate was calculated based on the 
linear regression and reflects how much of the surrogate substrate has been 
metabolised.  Typically the mean of 4 wells is presented. 
2.2.9. Microarray analysis 
Cor-1 cells were grown until 70% confluent in 10cm dishes for two days.  Next, the 
drugs were added to the fresh media at the following dilutions:  control (0.1% 
DMSO), AM251 (1µM), LY320135 (1µM), AM630 (1µM), JTE-907 (1µM), AG1478 
(100nM), PD168393 (100nM), PD173074 (500nM) (see Table 2.7 for further 
information on the drugs).  Structurally independent antagonists against the CB1 
and CB2 receptors as well as the EGFR receptor were used to reduce false-positive 
results based on off-target effects.  Cells then were lysed in RLT buffer (Qiagen), 
scraped off the plates under sterile conditions, and transferred to 1.5ml eppendorf 
tubes.  The samples were snap frozen on dry ice and the drug treatments were 
repeated 3-4 times on consecutive days.  Then the samples were shipped to Wyeth 
Research (now Pfizer) on dry ice, where the mRNA was extracted and used to 
perform microarrays based on the Affymetrix GeneChip Mouse Genome 430 2.0 
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array.  For further information on how the microarrays were conducted and 
analysed see (Suetterlin et al., Submitted) 
2.2.10.  Statistical analysis 
Two sided student t-test or anova (analysis of variance) in combination with Tukey 
post-hoc testing was used as indicated.  Some data was normalised setting the 
control to 100%.  This was done when data sets showed a lot of experimental 




CHAPTER III: Results 1 
Characterization of Cor-1 cells and the role of eCB signaling for their 
differentiation 
3. Characterisation of Cor-1 cells and evidence, that eCB signaling is 
important for proliferation 
3.1. Introduction 
The human brain contains a trillion neurons and a quadrillion of synapses (Ho et al., 
2011) and their connections define human perception, thoughts and emotions.  The 
brain is an extremely heterogeneous tissue making it challenging to uncover the 
molecular mechanisms underlying adult neurogenesis.  A number of cell culture 
model systems to investigate how new neurons are generated in the adult brain 
have been developed.  For example a “neurosphere” assay containing clusters of 
floating cells consisting of neural progenitor cells and their differentiating progeny 
has been adopted for this purpose by many labs (e.g Reynolds and Weiss, 1992; 
Morshead et al., 1994).  They have provided many insights into the factors that 
regulate neurogenesis in vitro; however their heterogeneous composition imposes 
limitations.  Three different homogeneous cultures of NSCs were established by the 
Austin Smith laboratory and kindly provided to us.  While CGR8 and NS5 cells are 
derived from embryonic stem cells and maintained at the NSC state, Cor-1 cells are 
derived from the E 16.5 mouse cortex (Conti et al., 2005).  This thesis will focus on 
Cor-1 cells as a model system.  The Cor-1 cells grow as an adherent NSC population 
and express a range of NSC markers and like their endogenous counterparts they 
can be differentiated into neurons, astrocytes, and oligodendrocytes (Conti et al., 
2005; Glaser et al., 2007).  Furthermore, they express the different components of 
the eCB system and depend on eCB signaling for proliferation.  They have proven to 
be a valuable tool to investigate the eCB system and establish their role in 




3.2. Characterisation of Cor-1 cells and evidence that eCB signaling is 
important for their proliferation 
Immunocytochemistry was used to confirm the continuous expression of NSC 
markers by the Cor-1 cells used in the present study.  The Cor-1 cells are a relatively 
homogenous cell population displaying a polarised morphology and expressing the 
NSC markers nestin and Sox2 amongst other markers (see Conti et al., 2005).  
Under normal growth conditions they do not express the astrocytic marker/ 
ependymal cell marker GFAP or the neural lineage marker neuron-specific class III 
β-tubulin (Tuj-1) (Figure 3.1).  The specificity of the anti-DAGLα and anti-DAGLβ 
antibodies was confirmed using cerebellar tissue from DAGLα and DAGLβ KO mice 
in comparison to wt tissue confirming the specific detection of the respective 
enzymes (Figure 3.2 A).  Furthermore the expression of eCB system components 
was established and the expression of CB1 receptor, FAAH and DAGLα were 
confirmed by immunocytochemistry and/or western blotting (Figure 3.2 B+C).  The 
expression of DAGLβ by Cor-1 cells has been shown elsewhere (Goncalves et al., 
2008). 
An in vitro proliferation assay has been established for Cor-1 cells.  The total cell 
number for cultures up to 72h has been demonstrated to be highly correlated with 
their confluence, provided confluence remains below ~80% (Dr. Philipp Sütterlin; 
PhD thesis).  Therefore, the proliferation of Cor-1 cells can be followed by 
measuring their confluence over time in culture.  Cor-1 cells were cultured in 96-
well plates at 8,000 cells/well and left to attach overnight.  An automated image 
analysis platform that is based on capturing and analysis phase-contrast images 
(IncuCyte imaging technology and software) was used to measure confluence every 
2h under normal cell growth conditions ± drug treatment.   
Cor-1 cell proliferation can be inhibited by CB1 and CB2 receptor antagonists and by 
two DAGL inhibitors, namely RHC80267 and THL (Goncalves et al., 2008).  A more 
selective DAGL inhibitor called OMDM-188 has recently been developed (Ortar et 
al., 2008) and the effect of this inhibitor on Cor-1 cell proliferation was determined 























In brief, 8,000 cells/well were seeded into a 96-well plate and left to attach 
overnight.  The cells were treated with 0-1µM OMDM-188 for 48h and cell 
confluence was determined every 2h using the IncuCyte imaging platform.  The 
cells looked healthy and had processes at all drug concentrations after the 48h 
treatment period (Figure 3.3 A).  Representative growth curves are shown in Figure 
3.3 B for a control culture and a culture treated with 0.5µM OMDM-188.  The area 
under the curve was calculated for three independent experiments at the stated 
concentrations and normalised to the control.  The relative area under the curve is 
shown Figure 3.3 C, demonstrating a significant reduction of ~25-35% in 
proliferation at 0.5 and 1µM OMDM-188.  This data supports the hypothesis that 
DAGL dependent eCB signaling is required for Cor-1 (Goncalves et al., 2008). 
3.3. Is eCB signaling required for Cor-1 cell differentiation? 
3.3.1. Effects of eCB receptor antagonists and agonist on neuronal 
differentiation   
A role for the eCB system in the proliferation and migration of Cor-1 and other NSC 
lines has been established (Goncalves et al., 2008; Oudin et al., 2011b).  It is not 
known, if eCB signaling is required for the differentiation of Cor-1 cells to neurons 
or glia.  I have differentiated Cor-1 cells towards a neuronal lineage using a B27 
based neuronal differentiation protocol adapted from Conti et al. 2005, with an 
example of this shown in Figure 3.4.  In brief, cells were grown on poly-ornithine 
and laminin coated 96-well plates in neuronal differentiation media for 7d with half 
the media being exchanged at day 4.  During this time at least a subpopulation of 
the cells keeps proliferating.  The media change causes some cells to wash off, 
which results in a dip in confluence and wider error bars after day 4 (Figure 3.4 B).  
By 4 days, the cells have developed more branches and longer processes which is 
indicative of adoption of a neuronal phenotype (Figure 3.4 A).  How quickly Cor-1 
cells display this morphology is highly dependent on initial seeding density and 


















The effect of CB1 and/ or CB2 receptor antagonist on neuronal Cor-1 cell 
differentiation was investigated.  Cor-1 cells were seeded at 20,000 cells/well in 4-
well plates onto poly-ornithine and laminin coated cover slips and left to attach 
overnight in expansion media.  The next day, the media was replaced with 
differentiation media as well as 1µM of a CB1 receptor antagonist (AM251) and/or 
a CB2 receptor antagonist (JTE-907).  After 2d half the media was replaced by fresh 
neuronal differentiation media containing fresh drugs.  The cells were grown for 
two more days and then fixed and stained for the neuronal lineage marker Tuj-1 as 
well as the fluorescent DNA binding dye Hoechst.  Tuj-1 positive cells as well as the 
total cell number were counted, and the % of Tuj-1 positive cells to total cell 
number is presented in Figure 3.5 E.  Cells were only counted if in focus and not in a 
cell cluster.  3 cover slips per condition were used for the analysis and the average 
of 3 independent experiments is presented.  On average, 20% of all cells are Tuj-1 
positive.  This is not changed by CB1 and/or CB2 receptor antagonism under the 
observed conditions.  The same experimental setup was also used to establish the 
effect of CB1 and/or 2 receptor agonists 1µM ACEA and 1µM JWH-133 on neuronal 
differentiation (Figure 3.6).  Neither CB1 nor CB2 receptor agonism changed the % 
of Tuj-1 positive cells to total cell number.  Combined these results show that 
neither CB1 and/or CB2 receptor antagonism nor CB1 or CB2 receptor agonism 
have an influence on the differentiation of Cor-1 cells towards the neuronal lineage.  
Thus the eCB signaling pathway is most likely not required for neuronal 
differentiation, nor does it stimulate it when activated in Cor-1 cells. 
3.3.2. The effects of eCB antagonists on astrocyte differentiation 
Cor-1 cells can also be differentiated to astrocytes using a BMP-4 or goat serum 
based protocol (adapted from Conti et al. 2005).  Cor-1 cells were seeded at 5,000 
cells/well onto gelatine coated 96-well plates, left to attach overnight, and the 
media was exchanged to BMP-4 astrocyte differentiation media.  The morphology 
of the cells was observed for 7d using IncuCyte live cell imaging.  At day 0, the cells 
display their cell typical polar morphology, but at day 4 a more star like morphology 
can be seen for most cells which is typical for astrocytes.  The cell body appears 

















The pictures of day 0, 4, and 7 show the same picture frame.  Even though cells do 
not seem to proliferate anymore, they remain mobile and move around (Figure 3.7 
A-C).  Undifferentiated Cor-1 cells do not express GFAP (Figure 3.1).  To analyse how 
many Cor-1 cells express the astrocytic marker GFAP after astrocytic differentiation, 
20,000 Cor-1 cells/well were seeded into 4-well plates containing gelatine coated 
glass cover slips, differentiated for 4d using a BMP-4 based astrocyte differentiation 
protocol and fixed.  The cells were stained with the DNA dye Hoechst and the 
astrocytic differentiation marker GFAP.  98% of all cells express GFAP and a 
representative picture is shown in Figure 3.7 D. 
To establish the effect of CB1 and/or CB2 receptor antagonism, 20,000 Cor-1 cells 
were seeded onto gelatine coated glass cover slips and left to attach overnight in 
expansion media and were then differentiated for 24h using a BMP-4 based 
protocol (Figure 3.8).  A subset was also treated with 1µM CB1 (AM251) or 1µM 
CB2 (JTE 907) receptor antagonists, the cells were fixed and stained with Hoechst, 
GFAP and Phalloidin.  Phalloidin is an F-Actin marker, used here to visualise the cell 
morphology and representative pictures are shown (Figure 3.8 A-C).  The BMP-4 
based protocol yields ~ 30% GFAP positive cells after 1d of differentiation (Figure 
3.8 D) and the CB1 and/or CB2 receptor antagonists had no effect on the 
percentage of GFAP positive cells.  This demonstrates that eCB signaling is not 
required for Cor-1 cell differentiation to an astrocyte lineage and similar results 
were obtained using the “goat-serum” based astrocytic differentiation protocol 
(results not shown). 
3.4. Characterization of DAGLα/β transfected cell lines 
The above results indicate that the eCB system does not play a role in the 
differentiation of Cor-1 cells to neurons or astrocytes.  We were interested to know 
if there might be a change in the expression and/or localisation of the DAGLs 
between the various lineages.  To this end we wanted to follow the endogenous 
























Cor-1 cell lines which overexpress DAGLα or β were established and made available 
for the study (provided by Dr. Philipp Sütterlin, Doherty lab).  The cell lines express 
an epitope-tagged DAGLα or DAGLβ under the CMV promoter and were named 
V5α7 and V5β5 respectively.   
Western blot analysis was performed to confirm expression of DAGLα-V5 and 
DAGLβ-V5 as well as to establish relative expression levels (Figure 3.9).  V5α7 and 
V5β5 cells were expanded in growth media and their proteins extracted and 
subjected to western blot analysis.  In this context, an anti-V5 antibody was applied 
and visualised using ECL.  V5α7 cells express the 120 kDa DAGLα-V5 construct.  A 
second band can be at about 260 kDa, suggesting the existence of a higher order 
DAGLα complex.  Between the bands seen at 120 and 260 kDa a diffuse staining can 
be seen, which might point towards glycosylation of DAGLα-V5.  It has to be 
mentioned, that using an endogenous anti-DAGL antibody, only one band at 120 
kDa was seen (Figure 3.2).  A single band at 70 kDa is seen in the V5β5 cells, which 
is the expected molecular weight for DAGLβ (Bisogno et al., 2003).  The expression 
of DAGLβ is considerably lower than the DAGLα expression seen in the V5α7 cells. 
The V5α7 and V5β5 cell lines were further characterized using 
immunocytochemistry (Figure 3.10).  20,000 cells were grown on gelatine coated 
cover slips, left to attach in expansion media overnight, fixed and used for 
immunocytochemistry.  Both cell lines continue to express the NSC marker nestin 
(Figure 3.10 A+B) and express the corresponding construct throughout the whole 
cell population.  No positive staining can be seen when native Cor-1 cells are 
stained with an anti-V5 antibody (data not shown).  DAGLα-V5 appears to be 
localized on the cell surface within the V5α7 cells (Figure 3.10 C+D), while DAGLβ-
V5 staining Figure 3.10 E+F) is punctuated and possibly retained to some extent 
within the endoplasmic reticulum.  We decided to take the DAGLα transfected cells 
forward for additional study based on the higher level of expression relative to the 














The morphology of Cor-1 and V5α7 was compared using immunocytochemistry.  
The cells were grown on gelatine coated glass coverslips at 20,000 cells/well in 4-
well plates and left in expansion media to attach overnight, fixed using PFA and a 
phalloidin dye was used to visualize the cell shape.  The Axio Vision LE imaging 
software was used to measure cell area (Figure 3.11 A) and process length (Figure 
Figure 3.11 C) and process number/cell (Figure 3.11 B) manually.  The cell area of 
Cor-1 cells is approximately 250µm2 and V5α7 cells have a tendency to have a 
smaller cell area of approximately 240µm2 however this is not a significant 
difference.  Both cell types have on average 2 processes, which have an average 
length of 23µm.  Thus overexpression of DAGLα is not obviously detrimental to the 
cells' morphology. 
3.5. DAGLα expression during Cor-1 differentiation 
3.5.1. DAGLα levels during neuronal differentiation 
The expression of DAGLα was examined in Cor-1 and V5α7 cells during 
differentiation to a neuronal phenotype.  Cor-1 cells were differentiated for 0-4 d 
with the neuronal differentiation protocol before protein extraction and western 
blot analysis.  An anti-DAGLα antibody was used to monitor DAGLα expression and 
was visualized using ECL and the result is shown in Figure 3.12.  Furthermore, Tuj-1 
is used to monitor the differentiation towards a neuronal lineage, which was 
expressed from day 3 onwards and actin served as a loading control.  A very 
substantial decrease in DAGLα expression was observed over the course of 
differentiation.  On neuronal differentiation day 1-3 only a faint band can be 
detected with the anti-DAGLα antibody and it is almost entirely absent by day 4.   
As is shown in Figures 3.13, only a proportion of cells (20-30%) express Tuj-1, when 
they are differentiated towards neurons.  To determine if astrocytes are also 
generated in the neuronal differentiation protocol, protein extracts were also 
analysed by western blot for the appearance of GFAP.  At day 1 of differentiation 
the astrocytic marker GFAP is also starting to be expressed, with expression further 























Therefore a mixed population of cells arises from Cor-1 cells using the neuronal 
differentiation protocol leading to an interest in the DAGLα expression levels in Cor-
1 cells differentiated upon astrocyte formation.  We moreover wanted to know if 
transfected DAGLα-V5 is regulated in the same way as the endogenous DAGLα, as 
this would suggest regulation at the level of protein expression rather than solely at 
the level of transcription.  
V5α7 cells were differentiated for 0-4d as described above; their protein was 
extracted and used for western blot analysis.  An anti-V5 antibody was used to 
detect DAGLα-V5 and a decrease in the expression is also seen, albeit at a slower 
rate than that observed for the endogenous DAGLα (Fig 3.12 C).  Tuj-1 expression 
was again used to confirm neuronal differentiation during this period and actin was 
used as a loading control.  When comparing DAGLα/DAGLα-V5 expression in Cor-1 
and V5α7 cells, a decrease in expression upon neuronal differentiation is observed 
in both cases.  This demonstrates that overall endogenous as well as overexpressed 
DAGL expression levels are reduced, and this suggests regulation by a means other 
than simply gene transcription (unless there is a coincidental loss of the different 
factors driving the endogenous and transgenic genes). 
Our results show that neurons and astrocytes are generated when Cor-1 cells are 
switched from their normal growth conditions to the “neuronal” differentiation 
conditions.  We wanted to test if DAGLα expression is down-regulated when Cor-1 
cells become neuronal.  To do this, Cor-1 or V5α7 cells were differentiated for 7d 
using the neuronal differentiation protocol and cell-type composition determined 
by immunocytochemistry (Figure 3.13).  Compared to the neuronal differentiation 
used for western blot analysis (Figure 3.12) a longer neuronal differentiation 
protocol was used for this experiment.  This allowed the initial low number of cells 
to spread out evenly.  Anti-DAGLα antibodies were used to test for co-expression in 
Tuj-1 positive cells (Figure 3.13 A+B).  The results clearly show that DAGLα 
expression is strongly reduced in Tuj-1 positive cells.  Similarly, DAGLα-V5 
expression was also significantly decreased in Tuj-1 positive V5α7 cells (Figure 3.13 
C).  Thus we can conclude that one feature of differentiation of Cor-1 cells to a 

















Considering that the endogenous enzyme and the overexpressed enzyme are 
expressed under different promoters, it is likely that the observed reduction in 
DAGLα expression levels seen in Figure 3.12 and 3.13 is related to regulation at the 
protein level.  In support of this we have been unable to detect any changes in 
DAGLα mRNA levels in undifferentiated and differentiated cultures of Cor-1 cells 
(Doherty lab, unpublished observation).  However, the mixed nature of the cell 
types found in the differentiated cultures complicates the picture and at this stage 
we cannot draw firm conclusions. 
3.5.2. DAGLα levels during astrocyte differentiation 
To determine if endogenous DAGLα levels changed during differentiation to 
astrocytes, Cor-1 cells were grown in the BMP-4 based astrocytic differentiation 
media for up to 3d before the proteins were extracted from the cells and analysed 
by western blotting.  A comparison of DAGLα and GFAP expression over the 3d 
period is shown in Fig 3.14 A alongside the actin loading control.  The band intensity 
was also measured using the Image-J software and DAGLα expression relative to 
actin is presented in Figure 3.14 B.  In contrast to the very rapid increase in GFAP, 
there is no change in the relative level of endogenous DAGLα over the 3d period.   
Next we wanted to determine if the expression levels of transfected DAGLα-V5 in 
V5α7 cells is changed during differentiation to astrocytes, and performed the same 
experiment as described above using the V5α7 cells.  In contrast to the result 
observed for Cor-1 cells where DAGLα expression remained unchanged, we observe 
a rapid up-regulation of DAGLα-V5 (Fig 3.14 C+D).  This result was unexpected, and 
as we did not see the same response with endogenous DAGLα, we have not 
explored the basis of it further.  This effect is most likely caused by enhanced 
activation of the CMV promoter in differentiated astrocytes, which drives the 
expression of the transfected DAGLα-V5.  The CMV promoter is a widely used 
promoter for transgene expression, but efficacy vary across different cells and is 
known to be affected by embryonic differentiation (Chung et al., 2002; Zeng et al., 
















3.6. Conclusions and discussion 
We have used the Cor-1 cell line as a model to address questions relating to the 
role of eCB signaling in the proliferation and differentiation of these cells to 
neurons and astrocytes.  The Cor-1 cells line can be continuously expanded while 
maintaining certain stem cell characteristics.  They have a doubling time of 
approximately 24h in our hands and keep expressing neuronal stem cell markers 
such as Sox2 and nestin (Figure 3.1) as has been described before (Conti et al., 
2005).  Moreover, they can be differentiated into astrocytes, neurons, and 
oligodendrocytes (Conti et al., 2005; Glaser et al., 2007).  Furthermore, they express 
eCB signaling enzymes and respond to them, as will be discussed below.  We 
therefore concluded that the Cor-1 cells are a suitable in vitro model to investigate 
the role of eCBs in neural progenitor cells.  As with other in vitro models, this 
imposes certain limitations and any findings need to be validated in vivo, which has 
been done successfully for certain aspects of our Cor-1 cells work in the context of 
proliferation and migration (Goncalves et al., 2008; Oudin et al., 2011b). 
NSC lines including the Cor-1 cells appear to express the DAGL enzymes at a higher 
level compared to other cell lines (Goncalves et al., 2008) and moreover DAGLα 
mRNA has been established by real-time PCR (PhD Thesis Dr Debbie Walker, 
Doherty lab).  CB1 as well as CB2 receptor expression has been shown on mRNA as 
well as protein level in NSC lines.  FAAH and MAGL can both break down 2-AG in 
vitro and therefore are a key part of the eCB signaling system.  While FAAH 
primarily breaks down anandamide in vivo, MAGL has been shown to mainly 
degrade 2-AG alongside other non-eCB monoacylglycerols (reviewed in De 
Petrocellis et al., 2004).  NSCs therefore express various components of the eCB 
system and the expression of CB1 receptor, FAAH, and DAGLα in Cor-1 cells has 
been verified in Figure 3.2. 
DAGLα is expressed by proliferating cells in the SVZ (Goncalves et al., 2008) while 
CB1 and CB2 receptors are expressed in progenitor cells of the hippocampus 
(Aguado et al., 2006; Palazuelos et al., 2008).  Moreover, DAGL and CB2 receptor 
antagonists can inhibit the proliferation of progenitor cells in mice and CB2 receptor 
agonism stimulates the proliferation of progenitor cells in vivo, which is an effect 
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more pronounced in older animals.  DAGLα, CB1, and CB2 receptors are expressed 
by nestin positive cells in neurospheres in vitro (Molina-Holgado et al., 2007).  Upon 
calcium-ionophore stimulations, neurospheres release 2-AG as well as lower 
amounts of anandamide (Aguado et al., 2005).  The proliferation of nestin-positive 
cells within neurospheres is increased when the CB1 receptor is stimulated either 
by a synthetic agonist or by preventing eCB breakdown which indicates that not 
only are eCBs being made by these cells but they are also able to react to eCB 
stimulation (Aguado et al., 2005).  The proliferation of cultured NSCs can be 
inhibited with DAGL as well as with CB2 receptor antagonists (Goncalves et al., 
2008).  These in vitro and in vivo results combined make a convincing case for 
neural progenitors being responsive to eCB signaling and that their proliferation is 
influenced by them.  The novel DAGL inhibitor OMDM-188 has been explored in this 
context and was shown to significantly inhibit Cor-1 cell proliferation (Figure 3.3). 
Next we wanted to investigate the role of the eCB system on differentiation.  Using 
a neuronal differentiation protocol adapted from Conti, Pollard et al. 2005, the Cor-
1 cells were differentiated and characterised.  At least a subpopulation of cells 
remains proliferative and cells display an elongated, more branched morphology 
after 4 to 7d of proliferation (Figure 3.4).  A mixed lineage population of cells, with 
some cells expressing the Tuj-1 neuronal marker, and other cells expressing the 
astrocytic marker GFAP (Figure 3.12) was generated, while other cells appeared to 
belong to yet other categories.  The inhibition or activation of CB1 and/or CB2 
receptors had no effect on the percentage of cells adopting a neuronal phenotype 
as assessed by Tuj-1 staining (Figure 3.5-3.6).  Thus we conclude that the eCB 
system does not play a key role in the differentiation of Cor-1 cells along the 
neuronal lineage in Cor-1 cells.  This is in line with in vivo findings showing that the 
number of cells committing to neuronal differentiation is not changed significantly 
in CB1 receptor or FAAH KO mice (Aguado et al., 2006).  In migratory neuroblasts 
travelling though the RMS however the eCB system has been shown to be involved 
in migratory processes such as nucleokinesis and cell branching displaying another 
role for the eCB system in neuronal differentiation (Oudin et al., 2011b). 
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In the hippocampus the CB1 receptor is expressed by astrocytes and is involved in 
the communication between astrocytes and neurons (Coiret et al., 2012).  This 
demonstrates a role for the eCB system in astrocytes and eCB signaling has been 
demonstrated to induce astroglial differentiation of neural progenitor cells in vitro.  
Moreover opposing astroglial differentiations patterns were observed for CB1 
receptor KO and FAAH KO mice.  While astroglial differentiation was decreased in 
CB1 receptor KO mice it was increased in FAAH KO mice (Aguado et al., 2006).  We 
therefore were interested in the role of eCB signaling in astrocyte differentiation of 
Cor-1 cells.  Using an astrocytic differentiation protocol, Cor-1 cells were 
differentiated to cells displaying a star shaped, astrocytic morphology and 
expressing GFAP (Figure 3.7).  CB1 and/or CB2 receptor antagonists had no effect 
on the differentiation of Cor-1 cells to astrocytes (Figure 3.8).  This indicates that 
the eCB system does not play a role in astrocytic differentiation of Cor-1 cells.  
Therefore the role of eCB signaling in astrocyte differentiation might be context 
dependent.  A role for the eCB system in oligodendrocyte differentiation has been 
reported (Gomez et al., 2010) and more recently the PI3 kinase/ Akt and mTOR 
pathway have been shown to be part of the signaling cascade in this context 
(Gomez et al., 2011). 
Cor-1 cell lines overexpressing DAGLα and DAGLβ were established (Dr Philipp 
Sütterlin; Figures 3.9-3.10).  For further studies on the enzymatic activity of 
DAGLα/β in these cell lines see Chapter 6, where a surrogate substrate assay was 
used to confirm the increased DAGL dependent enzymatic activity of these cell 
lines.  While DAGLα-V5 staining is observed throughout the whole cell surface, 
DAGLβ staining is very punctuated.  This also was observed in other clonal Cor-1 cell 
lines overexpressing the DAGLβ construct (PhD thesis Philipp Sütterlin).  While it is 
possible that DAGLβ is not localized to the cell surface in general, another 
possibility would be that DAGLβ needs another enzyme such as DAGLα to be 
correctly localized.  To test this hypothesis it would be necessary to double 
transfect the cells with DAGLβ as well as with DAGLα for example and analyse 
whether this leads to cell surface localization.  Compared to DAGLα, little is known 
about the expression pattern of DAGLβ.  In my opinion this reflects the absence - to 
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my knowledge - of a suitable DAGLβ antibody for immunostaining as well as the 
absence of selective DAGLα/β inhibitors.  Observations in the DAGLβ KO mice (Gao 
et al., 2010) should help to address this in the future and will help to distinguish 
between DAGLα and β functions.  Moreover other proteins might form complexes 
with DAGLα and/or DAGLβ, which might aid them in their localisation as well as 
functionality.  To date only two proteins are known to interact with DAGLα.  These 
proteins are Homer -1b and Homer-2 (Jung et al., 2007).  It would be very 
interesting to expand our knowledge about other potential interaction partners.  
Several proteins have been investigated in this context by our lab (unpublished 
data), but further evidence is needed to establish the possible relationship between 
the potential interaction partners and the DAGLs.  The DAGLα-V5 overexpressing 
cells were taken forward for further characterization and they do not display a 
significantly different morphology compared to the parental Cor-1 cells (3.11).  This 
indicates that DAGLα does not have an influence on Cor-1 cell shape. 
Next we wanted to establish the expression of DAGLα in neuronally differentiated 
Cor-1 cells.  To address this question, DAGLα expression was examined by western 
blotting over a 4d period of differentiation toward a neuronal phenotype.  A 
dramatic reduction in expression was seen, and this was recapitulated with an 
epitope tagged version of DAGLα expressed under the control of a CMV-promoter 
(Figure 3.12).  Immunocytochemistry confirmed a rapid reduction of endogenous 
and transgenic DAGLα in Tuj-1 positive cells (Figure 3.13), opening up the question 
of how DAGLα expression is reduced so quickly in these cells.  The rapid reduction 
of DAGLα in Tuj-1 positive interneurons is somewhat surprising given the proposed 
role of DAGLα for neurite outgrowth during development.  Some studies suggest 
that DAGLα is not expressed by GABAergic interneurons but by pyramidal 
interneurons neurons during development (Mulder et al., 2008).  Therefore it 
would be interesting to explore different neuronal differentiation protocols to 
create other types of interneurons and establish DAGLα expression in that context. 
Given the change in DAGLα during neuronal differentiation we wanted to establish 
the DAGLα expression levels during astrocytic differentiation of Cor-1 cells.  
Endogenous DAGLα expression was not changed significantly upon differentiation 
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of Cor-1 cells to astrocytes, however transgenic DAGLα-V5 expression increased 
quite dramatically (Figure 3.14).  The reasons for this are not as clear, but one 
obvious possibility is a higher activity of the CMV promoter in astrocytes as 
compared to undifferentiated Cor-1 cells.  
As mentioned above, DAGLα expression is significantly reduced in interneurons.  In 
the next chapter we therefore wanted to explore the possibility of DAGLα 
regulation on the protein level.  
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CHAPTER IV: Results 2 
Investigation of DAGLα degradation 
4. DAGL degradation 
4.1. Introduction 
Gene expression is usually controlled by transcriptional regulation, but post 
translational modifications allow an alternative regulation mechanism.  Very little 
information is available on the regulation of DAGL expression at the transcriptional 
or protein level.  Based on the observation that DAGLα expression is down-
regulated upon neuronal differentiation (see sections above) and our findings 
indicate that this is unlikely to be solely due to transcriptional regulation, we 
decided to investigate the post-transcriptional regulation of the DAGLs.  
Several proteins in neurons have been discovered to be targeted for degradation 
via a motif called a destruction box (d-box), which marks them for degradation via 
the ubiquitin-proteasome pathway (Hershko and Ciechanover, 1998; Hershko, 
2005).  A putative d-box has been identified in the DAGLα sequence and we wanted 
to investigate if this targets DAGLα for degradation.  Only 10-20% of the d-box 
sequence is conserved with the core sequence being RxxLxxxxN/D/E.  The single 
amino acid code of this sequence contains an invariable arginine and lysine, and it 
has been shown, that mutation of the invariant arginine prevents the degradation 
of cyclins (Glotzer et al, 1991).  The d-box marks the enzyme as a substrate for the 
ubiquitin ligase anaphase-promoting complex (APC) and substrate recruitment 
often requires a co-activator such as Cdh1 and Cdc20 (reviewed in Kim and Bonni, 
2007).  After the protein has been conjugated by one or more ubiquitin molecules, 
which is a highly conserved small protein, they are destined to be degraded by the 
26S proteasome.  The ubiquitin proteasome pathway is the most significant 
degradation pathway other than the lysosome pathway.  This degradation pathway 
carries out the selective degradation of many proteins in eukaryotic cells (Hershko 




4.2. Establishing a Cor-1 cell line expressing DAGLα-V5 with a silenced, 
putative d-box 
A putative d-box motif was discovered within the sequence of DAGLα via a 
bioinformatic approach (personal communications, Dr Gareth Williams).  We 
created a plasmid containing the DAGLα sequence expressed under the CMV 
promoter with the invariable arginine and lysine changed for alanines.  This should 
prevent d-box dependent degradation.  Cor-1 cells can be efficiently transfected 
using the AMAXA nucleofection technology and were nucleofected with the 
mutated d-box plasmid.  Stable Cor-1 cell lines expressing DAGLα containing the 
putative d-box mutations were selected in G418 containing media (see methods for 
details) and the most suitable cell line was selected based on western blot analysis 
and immunocytochemistry. 
Different clonal colonies were grown up and their V5-DAGLα-m-dbox expression 
levels were established (Figure 4.1).  The two clones showing the highest expression 
levels in preliminary experiments were Mα8 and Mα11.  They were grown up in 
selection media and their protein was extracted and used for western blot analysis.  
An anti-V5 antibody was used to compare expression levels of V5α7, Mα8, and 
Mα11 (Figure 4.1 B).  An anti-actin antibody was used as a loading control and Mα8 
displays a good expression level.  It is lower than the expression level seen in V5α7 
lysates, but considerably higher than the expression levels in Mα11 cells or the non 
selective cell line.  Immunocytochemistry was carried out to confirm a uniform 
expression throughout the Mα8 cell line and 100% of the cells are positive for 
DAGLα-V5-m-dbox (Figure 4.1 A).  This was deemed to be a suitable cell line to carry 
our further experiments. 
4.3. Neuronal differentiation of the Mα8 cell line 
The Mα8 cell line was used to determine if the mutation within the d-box had any 
effect on the loss of DAGLα expression previously seen during neuronal 
differentiation.  The expression levels of the DAGLα-V5-m-dbox in Mα8 cells at 0-4d 
of neuronal differentiation was monitored.  Similar to the situation seen with 
endogenous DAGLα, and the V5-tagged wt DAGLα, the expression levels of DAGLα-


































The relative expression levels normalised to 0d of differentiation relative to actin is 
presented in Figure 4.2 B.  The transgenic DAGL expression was compared between 
V5α7 and Mα8 cells and no fundamental difference was detected.  This indicates 
that the mutation within the putative d-box in the transgenic DAGLα-V5 enzyme 
does not affect the stability of the enzyme, with the same rate of loss seen upon 
neuronal differentiation. 
The Mα8 cells were seeded onto laminin and poly-ornithine coated glass cover slips 
and differentiated using a neuronal differentiation protocol as described earlier for 
7d.  Double labelling the cells with an anti-Tuj-1 and anti-V5 antibody (Figure 4.3) 
confirmed rapid reduction of the d-box mutated DAGLα from the Tuj-1 positive 
cells, indicating that the d-box mutation has no effect on down-regulation of DAGLα 
during neuronal differentiation.   
4.4. DAGLα can be ubiquitinated  
Our results point towards a d-box independent mechanism for DAGLα down-
regulation upon neuronal differentiation.  The ubiquitin-proteasome pathway is 
one of the most significant protein specific recycle mechanisms in mammalian cells.  
We therefore investigated the possibility that DAGLα might be ubiquitinated 
independently from a d-box motif.  IPs from the V5α7 cells using an anti-V5 
antibody were carried out and the samples were used for western blot analysis 
(Figure 4.4).  A generic anti-ubiquitin antibody was used to detect all ubiquitinated 
proteins within the lysate and multiple bands are detected in the lysate lane.  The 
most pronounced band however is found at 120 kDa, which is the molecular weight 
of DAGLα.  Using an anti-V5 antibody this band was confirmed to be DAGLα-V5.   
We next wanted to investigate the effect of neuronal differentiation on DAGLα 
ubiquitination.  V5α7 cells were differentiated for 4d using a neuronal 
differentiation protocol.  These cells as well as undifferentiated control cells were 
used for IPs using an anti-V5 antibody to pull down DAGLα-V5.  IPs without 
antibody were carried out as a negative control and these samples as well as lysate 



























An anti-ubiquitin antibody was used to detect all ubiquitinated protein and multiple 
bands were detected in the lysate band.  A band at 120 kDa is detected in the IP 
lanes, but not the negative IP bands for the differentiated as well as the 
undifferentiated V5α7 cells.  The membranes were stripped and an anti-V5 
antibody was used to confirm the 120 kDa band to be DAGLα.  The ubiquitin 
antibody clearly labelled the immunoprecipitated V5-DAGLα from both the control 
and differentiated cells (top panel in Figure 4.5), with the reduced level of labelling 
seen in the differentiated cells accountable for the reduced level of V5-DAGLα in 
the immunoprecipitate (bottom panel Figure 4.5).  This shows that DAGLα-V5 can 
be ubiquitinated in the differentiated cultures with no obvious evidence for any 
major change in this relative to the control cultures.  
4.5. Inhibition of proteasomal degradation 
Next we further wanted to establish, if DAGLα ubiquitination leads to its 
degradation via the proteasome.  Lactacystin is a selective inhibitor of the 
proteasome complex (Omura et al., 1991).  If ubiquitinylation of DAGLα-V5 leads to 
its degradation, the use of Lactacystin should prevent its degradation and increase 
its' expression levels.   
Cor-1 cells were treated with 0.5µM Lactacystin for 24h and pictures were taken 
every 2h with the IncuCyte platform (Figure 4.6) and the cell proliferation and 
morphology was observed.  Cor-1 proliferation was inhibited and cells processes 
appeared shorter.  Overall the cells appeared more rounded, but about 50% of the 
cells still had processes after 6h of Lactacystin treatment indicating that they were 
alive (Figure 4.6 A).   
To investigate the effect of proteasome inhibition on DAGLα protein levels, we 
treated Cor-1 cells with 0.5µM Lactacystin for 0, 2, 4, or 6h before extracting their 
protein for western blot analysis.  A DAGLα antibody that recognises the 
endogenous enzyme was used to quantitate expression, and as expected it 
recognised a single a band 120kDa (Figure 4.7).  Actin was used as a loading control.  
The intensity of the band was measured using the inbuilt Odyssey software and 














The expression was normalised to the control, and the mean of three independent 
experiments ± SEM is presented in Figure 4.7 B.  Although there was a trend 
suggesting a rapid increase, this was not significant due to the high variability 
between the three experiments.   
4.6. Conclusions and discussion 
Following our observation that Cor-1 cells differentiated to interneurons display a 
rapid decrease in DAGLα expression, we wanted to explore the mechanisms that 
regulate DAGLα degradation during differentiation.  Very little is known about post 
translational modifications of the DAGLs as well as other regulatory mechanisms.  
To investigate DAGL degradation a DAGLα-V5 overexpressing Cor-1 cell line with 
mutations in key residues in a putative d-box was established and called Mα8 
(Figure 4.1).  The cell line appears to be clonal as demonstrated by expression of the 
mutated construct in all cells.  Compared to the cell line V5α7 expressing wt DAGLα-
V5, expression levels in the Mα8 cells are slightly lower, but nonetheless at 
reasonable levels that are readily detectable.   
The effect of neuronal differentiation on transfected DAGLα levels in Mα8 cells was 
investigated.  V5α7 cells and Mα8 cells were differentiated for 0-4d.  In both cases a 
rapid drop in overall transgenic DAGLα-V5 expression was seen (Figure 4.2) as well 
as a rapid reduction in DAGLα-V5 expression in Tuj-1 positive cells (Figure 4.3).  
Together these results show that in the context of neuronal differentiation of Cor-1 
cells, the putative d-box has no effect on its degradation.   
The DAGLα-V5 plasmid with the d-box mutation plasmid was used for experiments 
using the hippocampi from E18 rats.  The hippocampi were dissected and 
nucleofected with 5µg of either the DAGLα-V5 plasmid or the DAGLα-V5 plasmid 
with the mutated d-box.  The cells were plated onto poly-lysine and laminin coated 
glass coverslips and grown for 2d under suitable conditions after which they were 
fixed and used for immunocytochemistry.  The cells were co-stained with Tuj-1 and 
V5 and in both cases, the DAGLα-V5 or DAGLα-V5 with a mutated d-box, V5 is 
present throughout the whole cell.  Co-stainings with V5 and Tuj-1 showing co-
localisation of V5 and Tuj-1 show that the d-box has no effect on DAGLα localization 
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in immature hippocampal neurons (Dr Madeleine Oudin, PhD thesis).  Following the 
same experimental set up, cells were grown for 14d before being fixed and used for 
immunocytochemistry.  The cells were stained for microtubule-associated protein 2 
(MAP2) which is enriched in neuronal dendrites and it was used for a co-staining 
with V5 showing that DAGLα-V5 is largely expressed in the dendrites.  This was not 
changed by the d box mutation indicating that the putative d-box is not involved in 
the exclusion of DAGLα from the axons in mature hippocampal neurons (Dr 
Madeleine Oudin, PhD thesis). 
To further investigate DAGLα degradation pathways we next wanted to investigate 
the ubiquitin proteasome pathway.  Protein degradation via both the proteasome 
as well as lysosome pathway can be directed via ubiquitination and are regarded as 
the most important degradation pathways in mammalian cells (Hershko and 
Ciechanover, 1998; Piper and Luzio, 2007).  As a first step we therefore investigated 
if DAGLα can be ubiquitinated.  IPs of DAGLα-V5 with an anti-V5 antibody revealed 
that the enzyme can be ubiquitinated (Figure 4.4).  This process was not obviously 
altered by neuronal differentiation (Figure 4.5).  Due to the very low levels of 
endogenous DAGL seen in differentiated culture, we were unable to verify this data 
for the endogenous DAGLα enzyme.  Since this observation was made in a DAGLα-
V5 overexpressing cells line it remains an open question if this form of post 
translational modification also occurs when the enzyme is expressed at a "normal" 
level. 
To further investigate the possibility of DAGLα being degraded via the ubiquitin 
proteasome pathway, we treated Cor-1 cells with 0.5µM lacatcystin, which resulted 
in inhibition of cell proliferation.  Inhibition of cell proliferation also has been 
observed in other studies of neuroblastoma cells such as Neuro-2a alongside 
inhibition of neurite outgrowth (Omura et al., 1991; Fenteany et al., 1994).  Higher 
concentrations lead to cell death within a short period of time (data not shown), 
which demonstrates the importance of protein recycling for cell health and cells 
seem to be more sensitive to Lactacystin treatment in comparison with for example 
epithelial cells (Fenteany et al., 1994).  If DAGLα is degraded via the proteasome 
pathway its' inhibition should lead to an increase in DAGLα protein levels.  We 
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therefore treated Cor-1 cells with 0.5µM Lactacystin between 0-6h and found no 
fundamental change in DAGLα expression levels in the observed time period.  It has 
to be mentioned, that a substantial variation was observed between experiments.  
Therefore further experiments are needed to establish the role of the proteasome 
complex for DAGLα degradation.  
To further investigate the ubiquitination status of DAGLα, an E1- ligase inhibitor 
could be used.  While cells have multiple E2 and E3 type enzymes, they typically 
only have one E1 ligase.  Such type of inhibitor has been described and would 
theoretically inhibit all ubiquitination events in the cell (Yang et al., 2007).  
Alternatively other inhibitors blocking protein ubiquitin related protein degradation 
like Bortezomib could be used (Adams and Kauffman, 2004).  In order to narrow 
down the exact ubiquitination process, pseudosubstrate inhibitors like Emi1 could 
be used to inhibit the APC complex and other parts of the ubiquitination process 
(Reimann et al., 2001; Straiker et al., 2009).  Ubiquitin also has been shown to 
potentially play a role in lysosomal degradation.  In the context of 
neurodegenerative diseases ubiquitin conjugated protein clusters have been found 
in presumably lysosomal complexes (Blommaart et al., 1997).  Lysosome specific 
inhibitors are also available and could be used to explore this line of degradation 
(Qin et al., 2003).  
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CHAPTER V: Results 3 
Upstream and downstream cascade of DAGLα/eCB signaling in Cor-1 cells 
5. Regulation 
5.1. Introduction 
Optimal growth of Cor-1, and other NSC lines, is dependent on a mixture of 
nutrients as well as growth factors such as EGF and FGF-2 (Conti et al., 2005; Sun et 
al., 2008).  Furthermore, these growth factors play an important role in 
neurogenesis in vivo (Tropepe et al., 1997; Zhang et al., 2004) and play a crucial role 
in the generation of NSC cultures (Pollard et al., 2006).  Whereas EGF is crucial for 
maintaining cell survival and proliferation, absence of FGF-2 signaling only 
decreases cell proliferation (Pollard et al., 2006).  The EGFR and FGFR are both 
receptor tyrosine kinases (RTKs) and are well placed to regulate DAGLα/β activity 
through PLCƴ.  Furthermore, the FGFR has been demonstrated to be upstream of a 
DAGL-eCB response during development and to mediate neurite outgrowth as well 
as path finding (Williams et al., 2003).  Another substance which stood out from the 
nutrient mix is insulin.  In order to adapt to environmental changes, stem cells have 
to be able to detect and react to metabolic fluctuations (Speder et al., 2011) and 
insulin signaling was recently linked to brain cell progenitor proliferation (Hodge et 
al., 2004; Popken et al., 2004; Lehtinen et al., 2011).  
Cor-1 and other NSC lines have an endogenous eCB tone that drives proliferation, 
with nothing known about how this tone is generated.  Given the established cross-
talk between receptor tyrosine kinases and eCB signaling, we wanted to determine 




5.2. What drives eCB signaling? 
5.2.1. Micro array analysis comparing eCB, EGFR and FGFR signaling 
One way to determine the relationship between EGF, FGF, and eCB signaling is to 
identify the transcripts regulated by each receptor and see if the transcriptional 
responses are related.  We used a microarray approach to analyse the 
transcriptional response of eCB as well as EGFR and FGFR signaling in Cor-1 cells 
and compared the responses.  Two structurally independent CB1 (1µm AM251, 
1µM LY320135) and CB2 (1µM AM630 and 1µM JTE907) receptor antagonists were 
used.  Furthermore the EGFR antagonists AG1478 and PD168393 (both 100nM) and 
FGFR antagonist PD173074 (500nM) were used.  Drugs were dissolved in 1000X 
DMS0 and compared with a 0.1% DMSO treated control.  Cor-1 cells were grown on 
T75 tissue culture flasks and treated for 4h with the respective antagonists.  The 
mRNA was extracted in RLT buffer (Qiagen RNeasy kit) and frozen on dry ice.  
Samples were collected on three independent and consecutive days for all 
treatment groups as well as the control.  The micro array analysis was carried out 
by Wyeth Research (now Pfizer) collaborators in Boston.  The data of three different 
days was averaged and compared to the control.   
To analyse the microarray date, values below 20 were excluded and treatment 
response was defined as  
   
   
 with t being the average treatment value and c being 
the average control value.  Statistical significance was established using the student 
t-test.  Significant responders to AM251 treatment were compared with all 
responders to LY320 treatment.  Pearson's correlation coefficient r created values 
between -1 and 1.  The correlation coefficient of r=0.7590 between AM251 and 
LY320 is very high (Figure 5.1 A).  A similar result was obtained when comparing the 
significant AM630 responders with the total JTE970 (Figure 5.1 B).  Based on their 
high correlation, the CB1 receptor responders obtained with the AM251 and LY320 
and CB2 receptor responders to AM630 and JTE907 were pooled and compared 
with each other (Figure 5.1 C).  The correlation coefficient of r=0.7970 confirms a 
strong correlation between CB1 and CB2 receptor signaling.  This demonstrates that 
CB1 and CB2 receptors have a similar transcriptional response in Cor-1 cells.  



















Again, a very strong correlation was observed when comparing the two EGFR 
antagonists (data not shown) and therefore responders were pooled for 
comparison with the CB1/2 receptor responders (Figure 5.1 E).  A mild correlation 
was observed (r=0.4128), whereas the correlation coefficient between the FGFR 
inhibitor and eCB inhibitors does not show any correlation (Figure 5.1 D).  These 
data do not support the hypothesis that FGFR signaling drives the eCB response as 
if this were the case the transcripts regulated by the eCB receptors would be 
expected to be regulated by the FGFR.  The alternative hypothesis that the EGFR 
drives the eCB response is not disproven, and will be investigated further below.   
Comparing the range of transcriptional response between eCB, EGFR and FGFR it is 
noticeable (Table 5.1), that the range and amount of responders is considerably 
different.  While 1362 responders were significantly changed in the pooled CB1/2 
receptor microarray sets twice as many responders were significantly changed 
when treated with EGFR antagonists.  The range of responses is also different 
ranging between -0.61 and 0.58 for the eCB responder, - 1.52, and 1.82 for the 
EGFR responders and -0.5 and 0.79 for the FGFR responders.  This shows that EGFR 
antagonist treatment results in a broader and more intense change in 
transcriptional response when compared with eCB antagonist treatment or FGFR 
antagonist treatment.   
5.2.2. The effect of EFG, FGF and insulin on Cor-1 proliferation 
Next we wanted to establish the relevance of EGF and FGF-2 for Cor-1 proliferation.  
Cor-1 cells were grown on gelatine coated 96-well plates in growth media, while the 
supplemented growth factors were adjusted depending on the experiment and live 
cell imaging using IncuCyte technology was used to visualise proliferation.  Cor-1 
cells were grown without FGF-2 supplementation, and a reduction in Cor-1 
confluence was observed (Figure 5.2 A), but cells remain healthy and proliferating.  
The reduction of EGF below the usual 10ng/ml leads to a drastic reduction in Cor-1 



















Based on the partial overlap in responders seen in Figure 5.1 between eCB and 
EGFR responders we next investigated if eCB agonists can boost Cor-1 proliferation 
in reduced EGF conditions as might be expected if eCB signaling was downstream 
from EGFR signaling.  AM251 and JHW 133 (both at 1µM) were added to cells 
grown without or at 1ng/ml EGF, but no significant difference is detected between 
CB1+2 receptor agonist treated and untreated cells (Figure 5.2 C).  This shows that 
eCB signaling cannot recover Cor-1 proliferation under low or no EGF conditions.  
While it is possible that EGF signaling drives eCB signaling in other contexts, this 
shows that it is unlikely to drive eCB signaling in the context of Cor-1 proliferation.   
Next we investigated the effect of insulin withdrawal on Cor-1 proliferation (Figure 
5.3).  Insulin is part of the commercial N2 supplement added to the media to create 
the growth media.  To vary insulin levels, an "in house" N2 was used and insulin was 
separately added.  We compared Cor-1 proliferation using an IncuCyte live cell 
imaging.  No difference was detected between the commercial and the in house N2 
and cells looked healthy and proliferated at the same rate (Figure 5.3 A).  Cor-1 cells 
were grown with in-house N2 containing insulin (Control) or no insulin and CB1/2 
receptor agonists (0.5µM ACEA and JWH 133) or antagonists were added (1µM 
AM251 and JTE-907).  Cor-1 cells were grown for 24h and live cell images are taken 
every 2h and the confluence was calculated using IncuCyte software.  The area 
under the curve was calculated using an Excel macro and normalised to the control.  
The average of 3 experiments is shown in Figure 5.3 D demonstrating a significant 
reduction of confluence in cells grown without insulin.  Confluence can be further 
reduced using CB1/2 receptor antagonists and can be restored to control 
confluence levels using CB1/2 receptor agonists.  Therefore insulin might drive eCB 






















To further investigate insulin signaling, we wanted to establish if the insulin 
signaling related receptors are present in Cor-1 cells.  We identified the insulin 
receptor (InsR), the β chain of InsR and the IGFR to be present by 
immunocytochemistry and/or western blot analysis (Figure 5.4).   
H-1356 is an inhibitory IGF-1 peptide analog inhibiting the IGFR.  It was used at 
concentrations between 0-1µM in an IncuCyte live cell imaging based Cor-1 
proliferation assay (Figure 5.5).  No fundamental changes in cell proliferation or 
shape were observed.  It therefore appears that the IGFR is not involved in 
regulation of proliferation in Cor-1 cells. 
AG1024 inhibits the IGFR as well as InsR activity.  10nM has been shown to inhibit 
cancer cell proliferation (Wen et al., 2001).  It was used at concentrations between 
0-0.5µM.  At higher concentrations it induced cell death, but at lower 
concentrations it reduced cell proliferation significantly (Figure 5.6).  This result 
supports the result seen in Figure 5.3, where cells showed reduced proliferation 
upon insulin withdrawal.   
In summary, based on the lack of a transcriptional response overlap between CB1/2 
receptor signaling and FGFR signaling (Figure 5.1) we conclude that FGFR is not 
upstream of the CB1/2 receptor in Cor-1 cells.  Furthermore, Cor-1 proliferation 
only is reduced by ~30% in the absence of FGF-2, while Cor-1 cell cannot proliferate 
in the absence of EGF (Figure 5.2).  The transcriptional response between the 
different CB1 and CB2 receptor drugs showed a remarkably strong correlation.  A 
smaller overlap between the transcriptional response of CB1/2 receptor signaling 
and EGFR receptor was identified (Figure 5.1).  This might indicate that they share a 
common downstream pathway.  Based on the micro array data, the mammalian 
target of rapamycin (mTOR) pathway was identified as a promising downstream 
pathway (personal communication with Dr Gareth Williams) and was further 








































Based on the observation that eCB signaling can partially compensate for loss of 
insulin signaling, I would suggest that this looks like the best candidate to be the 
growth factor that generates eCB tone, however due to time constraints I have 
been unable to obtain direct evidence to support this hypothesis, and other 
additional pathways need to be upstream driving the CB1/2 receptors as well since 
Cor-1 proliferation can be further reduced by eCB inhibitors in the absence of 
insulin (Figure 5.3).  In this context of Cor-1 proliferation the InsR is a more likely 
candidate than the IGFR to be involved in this process.   
5.2.3. Investigation of kinases suspected to be upstream of the CB1/2 
receptors and influencing CB1/2 receptor signaling 
Growth factor receptor signaling cascades often include a series of phosphorylation 
events via kinases as has been well established for many pathways such as the 
mitogen-activated protein kinase (MAPK) signaling pathway (reviewed in McCubrey 
et al., 2007).  Combining bioinformatic approaches, existing experimental data and 
our own unpublished observations we predict that DAGLα is phosphorylated (for 
more information see below).  Especially PKA and PKC have been identified as 
strong candidates to phosphorylated DAGLα.  Based on this I wanted to test a 
number of kinases to see if the activity was required upstream of the CB1/CB2 
receptor response.  A straightforward logic was applied – if a kinase inhibitor could 
block proliferation and this could be recovered by CB1/CB2 receptor agonists, then 
that kinase might be considered as a candidate for generating eCB tone, perhaps via 
phosphorylation and activation of DAGL. 
Bioinformatic tools were used to identify phosphorylation sites on the hDAGLs to 
predict kinases that might be responsible for this.  PhosphoSitePlus 
(www.phosphosite.org) for example is an online resource giving comprehensive 
collections of data on post translational modifications including phosphorylation 
while NetPhospho 2.0 is another bioinformatics tool to identify phosphorylation 
sites and hDAGLα was investigated.  A high score of 0.998 (1 being the highest score 
possible) for S402 was revealed for hDAGLα indicating a very high likelihood for 






















DAGLα and DAGLβ were investigated using these and other tools to identified 
phosphorylation sites (Figure 7.2).  Furthermore, we predict that DAGLα 
phosphorylation is important for its active configuration status based on 
comparisons with other α/β hydrolases (Reisenberg et al., 2012 ).   
Amongst other databases the Human Protein reference database allows recognition 
of kinase substrate sites and helped to identify possible kinases.  Furthermore, PKA 
was shown to positively regulate phosphorylation of DAGL purified from brain 
microsomes (Perez Roque et al., 1998; Rosenberger et al., 2007).  PKC and PKA have 
been shown to increase 2-AG synthesis, most likely via a DAGL-dependent 
mechanism (Vellani et al., 2008).  PKA, PKC, CamK II, and CDK have been identified 
as good candidates to investigate regarding DAGL phosphorylation based on the 
data mentioned above and observations obtained with a CB1 receptor activation 
assay (Emma Williams, unpublished observations).  
Kinase inhibitors for CamK II (KN62), CDK 1, 2, 5 (Roscovitine), PKA (H89) and PKC 
(Go6976) were investigated in the context of DAGLα activity.  Their effect on Cor-1 
proliferation was investigated using live cell imaging with the IncuCyte.  We wanted 
to establish if the kinase inhibitors have an effect on Cor-1 proliferation and if this 
effect can be rescued using CB1/2 receptor agonists.  This would be a good 
indication that a phosphorylation event upstream of the CB1/2 receptors 
influenced receptor signaling potentially via 2-AG synthesis.  Cor-1 cells were 
treated with 0-5µM KN62, 0-10µM roscovitine, 0-5µM H89 and 0-1µM Go 6976 and 
cell confluence was measured for 48h using IncuCyte live cell imaging and software.  
All investigated kinase inhibitors inhibited Cor-1 proliferation in a dose dependent 
manner (data not shown).  Next we wanted to investigate if CB1/2 receptor 
agonism could reverse this inhibition.  Cor-1 cells were treated with 1µM KN62, 
1µM roscovitine, 5µM H89 or 1µM Go6976 ± CB1/2 receptor agonists (1µM ACEA 
and 1µM JWH-133) and grown for 48h under these conditions.  Proliferation was 
observed using IncuCyte live cell imaging and representative confluence curves are 




















In the cases of KN62 (Figure 5.7 A) and roscovitine (Figure 5.7 B) the additional 
treatment with CB1/2 receptor agonists did not increase proliferation.  H89 and 
Go6976 treatment reduced Cor-1 confluence and this could be increased by using 
CB1/2 receptor agonists.  In the case of H89, the confluence remains lower than 
under control conditions, while in the case of Go6976, the confluence was restored 
to control conditions if treated with Go6976 and CB1+2 receptor agonists (Figure 
5.1 C+D).  It has to be mentioned that the cell morphology is changed by Go6976 
treatment. 
The area under the curve was calculated using an Excel Macro, normalised to the 
control and data from 3 independent experiments is presented in Figure 5.7 E.  
Treatment with all kinase inhibitors significantly decreased the relative area under 
the curve as calculated by using the student t-test and no change in proliferation 
was observed using KN62 or roscovitine.  The treatment with H89 plus CB1+2 
receptor agonists led to an enhanced Cor-1 proliferation which is a not significant 
trend.  Only the inhibition of proliferation and/or change in morphology induced by 
Go6976 could be significantly increased by CB1/2 receptor agonist treatment.  This 
might indicate a role of PKC in eCB signaling upstream of the CB1 and/or CB2 
receptors.  To test if this effect is a DAGL related effect further experiments are 
needed.  One possibility would be via the use of phospho specific DAGLα antibodies 
which are not commercially available so far.  Therefore our lab created 5 possible 
DAGLα-phospho antibodies and these as well as commercially available, generic 
kinase substrate antibodies were tested (data not shown).  While the generic kinase 
substrate antibodies were not suitable, further experiments are needed to establish 
the suitability of the phospho-DAGLα antibodies.  Furthermore, an assay to 
investigate DAGL activity has been published recently (Pedicord et al., 2011) and 
was tested for its suitability in combination with Cor-1 cells in Chapter 6. 
5.3. Is mTOR/p70 S6 kinase downstream of EGFR, FGFR and/or eCB 
signaling? 
As mentioned earlier an overlap of transcriptional responds between CB1/2 




















While the correlation was not strong enough to account for the EGFR signaling 
driving eCB signaling in Cor-1 cells, it opened up the possibility that they might 
share a common downstream signaling hub.  The mTOR pathway was identified as a 
promising candidate based on the acquired microarray data (personal 
communication Dr Gareth Williams,).  This is also supported by recent publications 
linking the mTOR pathway to eCB signaling (Gomez et al., 2011; Keimpema et al., 
2011; Palazuelos et al., 2011). 
mTOR signaling is linked to a wide range of extra- and intracellular signaling 
mechanisms (Laplante and Sabatini, 2009).  Growth factor signaling via the EGFR or 
IGFR as well as insulin, nutrients or stress is known to regulate mTOR signaling and 
the most common signaling pathway is through the PI3K/Akt pathway.  The EGFR is 
known to signal via AKT/mTOR especially in carcinoma cells and other cancer cells 
(Han et al., 2006; O'Reilly et al., 2006; Freudlsperger et al., 2010).  Furthermore, the 
mTOR/p70 S6 kinase (in Figures referred to as p70) pathway has been 
demonstrated to be modulated by CB1 receptor signaling in the mouse 
hippocampus (Puighermanal et al., 2009).  Moreover, CB1/2 receptor agonism has 
been shown to increase oligodendrocyte differentiation via the mTOR and Akt 
signaling pathway (Gomez et al., 2011).  Considering the partial overlap of 
transcriptional responses seen in the eCB and EGFR microarrays (Figure 5.1) and the 
previously mentioned findings, we wanted to investigate if EGFR and the CB 
receptors signal via the mTOR pathway.   
We first wanted to confirm the role of mTOR signaling in Cor-1 cell proliferation, by 
using the mTOR inhibitor rapamycin (Figure 5.8).  Rapamycin was used at 
concentrations between 0 and 2µM in an IncuCyte base Cor-1 cell proliferation 
assay and was seen to inhibit cell proliferation.  Moreover, the relative area under 
the curve was calculated for three independent experiments and rapamycin 
significantly inhibited the relative area under the curve even at the lowest used 
rapamycin concentration of 0.1µM (Figure 5.8 B) while Cor-1 cells looked healthy 





















The p70 ribosomal S6 kinase is a downstream target of mTOR and is activated by 
mTOR through phosphorylation and the mTOR/p70 S6 kinase pathway furthermore 
has been linked to cell proliferation (Wing et al., 2005; Varma and Khandelwal, 
2007).  To test if mTOR phosphorylates p70 S6 kinase in Cor-1 cells, we grew Cor-1 
cells in the presence of 500nM rapamycin for 0-4h (Figure 5.9 A) or at different 
rapamycin concentrations between 0 and 0.5µM (Figure 5.9 B).  Western blot 
analysis was performed and an anti-p70 S6 kinase (p70) and anti-phospho-p70 S6 
kinase (phospho-p70) antibody was used to observe the influence of rapamycin 
treatment on the protein and its phosphorylation.  While p70 S6 kinase levels 
remain even, its phosphorylation detected by phospho-p70 is not observed 
between 0.5-4h of rapamycin treatment.  We therefore demonstrated that p70 S6 
kinase is a downstream target of mTOR in Cor-1 cells and furthermore p70 S6 
kinase phosphorylation, which is required for its activation, can be inhibited with 
the mTOR inhibitor rapamycin. 
Next, we wanted to establish the effect of EGFR or FGFR treatment on the state of 
p70 S6 kinase.  To test this, we treated Cor-1 cells with the EGFR inhibitor AG1478 
or FGFR inhibitor PD173074 (Figure 5.10).  We extracted the proteins and used 
them for western blot analysis.  The drug treatment and protein extraction were 
carried out and samples were provided by Dr Philipp Sütterlin.  Anti-p70 and anti-
phospho-p70 antibodies were used to detect p70 S6 kinase and its phosphorylated 
form.  While p70 S6 kinase remained even with both treatments (Figure 5.10 A, C), 
phospho-p70 levels were significantly reduced after 4 h EGFR inhibitor treatment 
(Figure 5.10 A, B), but unchanged by FGFR inhibitor treatment (Figure 5.10 C, D).  
This indicates that mTOR/p70 S6 kinase is downstream of the EGFR. 
After establishing the relationship between EGFR and p70 S6 kinase activation in 
Cor-1 cells we next wanted to investigate if there is a relationship between eCB 
signaling and p70 S6 kinase activation.  To do so, we treated Cor-1 cells with 
AM251, JTE-907 or both (all at 1µM) for 4h before extracting the proteins and using 
them for western blot analysis (Figure 5.11).  No significant change in phospho-p70 
levels was observed when treating the cells with AM251 and/or JTE-907.  p70 S6 


















This shows that even though the mTOR/p70 S6 kinase pathway is downstream of 
EGFR signaling in Cor-1 cells, it is not downstream of eCB signaling. 
5.4. Conclusions and discussion 
The eCB system has a role in neurogenesis and NSC proliferation (Goncalves et al., 
2008; Oudin et al., 2011a).  While the FGFR has been shown to be upstream of eCB 
signaling in another context (Williams et al., 2003) it is not known what drives eCB 
signaling in NSCs.  We used the Cor-1 cells as a model system to explore this as well 
as some other aspects of eCB signaling.  We used micro array analysis to address 
the question if there is a transcriptional overlap between EGFR, FGFR and/or CB1/2 
receptor signaling.  A strong overlap would be a reasonable indicator for the EGFR 
and or FGFR to be upstream the CB receptors.  A very high correlation was seen 
between the used CB1 receptor antagonists as well as the CB2 receptor antagonists 
and furthermore with each other (Figure 5.1).  This first of all is proof of principle 
confirmation that we were able to compare receptor signaling efficiently with each 
other and moreover shows that CB1 and CB2 receptors signal via very similar 
pathways in Cor-1 cells.  The comparison between FGFR inhibition and CB1/2 
receptor antagonist shows a very small correlation indicating that FGFR is not 
upstream of the CB receptors in Cor-1 cells while they are proliferating under 
normal growth conditions.  Moreover, while FGF-2 was found to be of some 
importance for Cor-1 proliferation, cells were able to proliferate in the absence of 
FGF-2 (Figure 5.2).  Together this indicates that it is unlikely that FGFR is upstream 
of CB1/2 receptor signaling. 
A smaller overlap between the transcriptional response of CB1/2 receptor signaling 
and EGFR receptor was identified (Figure 5.1).  Moreover, the EGFR does not 
appear to be directly upstream of eCB signaling in the context of Cor-1 cell 
proliferation, as CB1/2 receptor agonism cannot recover Cor-1 cell proliferation in 
low or no EGF conditions (Figure 5.2 B).  While there are several interpretations, 
one particularly plausible possibility would be a common downstream pathway and 
the mTOR pathway appeared to be particularly promising (personal communication 
with Dr Gareth Williams) and was further investigated. 
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Stem cells can adapt to metabolic fluctuations (Speder et al., 2011) and 
furthermore the eCB system has a role in energy balance regulation via the CB1 
receptor (discussed in Rivera et al., 2011).  Moreover brain cell progenitor 
proliferation has been linked to insulin signaling (Hodge et al., 2004; Popken et al., 
2004; Lehtinen et al., 2011) and insulin is also present in the growth media the Cor-
1 cells are grown in making insulin signaling an attractive target to investigate in the 
context of eCB driven proliferation.  Since insulin is present in the N2 supplement, 
as a first step we had to test an "in house" N2 supplement to be able to grow the 
Cor-1 cells in insulin free media.  We compared Cor-1 cell proliferation using the 
commercial and "in house" N2 supplement and no difference was observed (Figure 
5.3 A).  Cor-1 cell proliferation is significantly reduced in the absence of insulin 
(Figure 5.3 D).  While CB1+2 receptor agonists treatment restores Cor-1 
proliferation in the absence of insulin back to near normal proliferation levels, the 
proliferation could be further reduced using a CB1+2 receptor antagonist in the 
absence of insulin.  This indicates that insulin signaling is perhaps upstream of 
CB1/2 receptors, but other signaling pathways have an additional effect, and more 
direct evidence would be required to test this hypothesis.  To further investigate 
the relationship between insulin signaling and CB1/2 receptor signaling in Cor-1 
proliferation we wanted to establish which insulin detecting receptors are 
expressed by the Cor-1 cells.  The IGFR is for example expressed by cortical 
progenitor cells during development (Lehtinen et al., 2011) while cell proliferation 
in the adult rodent SGZ is impaired in insulin-deficient and insulin resistant rodents 
(Stranahan et al., 2008; Ming and Song, 2011).  There is some evidence at the 
protein level that InsR as well as the IGFR are expressed by the Cor-1 cells (Figure 
5.4), but while the tested IGFR inhibitor showed no effect on Cor-1 proliferation 
(Figure 5.5), a promising reduction of Cor-1 cell proliferation was observed using 
the InsR and IGFR inhibitor AG1024.  In this context of Cor-1 proliferation the InsR is 
a more likely candidate than the IGFR to be involved in this process since the IGFR 
inhibitor did not show an effect.  However further experiments are needed to 
confirm this.   
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The MAPK cascade is a very prominent example for the mediation of receptor 
activation via phosphorylation events (Choi et al., 2008).  As previously discussed, 
there are compelling indications for DAGLα and DAGLβ to be phosphorylated and 
we wanted to investigate possible kinases carrying out their phosphorylation in the 
context of Cor-1 proliferation.  PKA, PKC, CaM kinase, and CDK 1,2,5 have been 
identified as the best candidates (personal communication Emma Williams, 
unpublished observations) to carry out the phosphorylation.  Kinase inhibitors 
against the respective kinases were used in a Cor-1 proliferation experiment and all 
lead to an inhibition of proliferation (Figure 5.7).  Treatment with CB1/2 receptor 
agonists did not recover Cor-1 proliferation in the presence of the CaM kinase or 
CDK1,2,5 indicating that the inhibited phosphorylation events are not upstream of 
CB1/2 receptors and therefore unlikely to be DAGL related.  The reduction of the 
PKA inhibitor treatment at least partially was elevated by CB1/2 receptor agonist 
treatment but this however was not a significant elevation in the tested conditions.  
Treatment with the PKC inhibitor led to a change in Cor-1 morphology and/or 
proliferation, which could be significantly recovered by CB1/2 receptor agonist 
treatment.  Further experiments are needed to establish if this is due to the 
recovery of proliferation or changed morphology, however in either case the results 
indicated that a phosphorylation event upstream of the CB1/2 receptors is involved 
in the change.  It has been reported that PKA and PKC are involved in 2-AG level 
control possibly via the DAGLs (Vellani et al., 2008) and an effect via PKC 
phosphorylation on DAGL activity has been described elsewhere (Perez Roque et 
al., 1998).  Moreover PKC has been demonstrated to affect other components of 
the eCB system by phosphorylating the CB1 receptor and thereby disrupting its 
activation (Garcia et al., 1998).  Taken together, these results highlight that PKC in 
particular is likely to be involved in DAGL phosphorylation. 
As mentioned above, we hypothesize that the mTOR pathway is a common 
downstream pathway of the EGFR and CB1/2 receptors.  As a first step we wanted 
to establish the effect of the mTOR inhibitor rapamycin on Cor-1 proliferation and 
observed a rapamycin mediated reduction in Cor-1 proliferation (Figure 5.8) and 
thereby establishing the relevance of mTOR pathway for Cor-1 proliferation.  Next, 
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we established that mTOR inhibition by rapamycin leads to a loss of 
phosphorylation of p70 S6 kinase (Figure 5.9).  While not being the only 
downstream target of mTOR, the p70 S6 kinase has been demonstrated to be 
important for cell proliferation and therefore was chosen for this investigation 
(Wing et al., 2005; Varma and Khandelwal, 2007).  Cor-1 cells were treated with 
either EGFR, FGFR (Figure 5.10) or CB1 and/ or CB2 receptor inhibitors (Figure 5.11) 
and the effect on the phosphorylation status of p70 S6 kinase was observed.  More 
precisely the phosphorylation of threonine 389 which is closely linked to p70 S6 
kinase activation (Weng et al., 1998) was investigated using western blot analysis.  
Treatment with the EGFR inhibitor led to a loss of phospho p70 S6 kinase, while not 
changing overall p70 S6 kinase levels.  This goes hand in hand with the observation 
that EGF or insulin treatment led to phosphorylation of p70 S6 kinase (Galbaugh et 
al., 2006).  FGFR inhibitor treatment on the other hand had no effect on the 
phosphorylation status of p70 S6 kinase in our hand, neither had the CB1 and/or 
CB2 receptor inhibitors.  These results indicate that p70 S6 kinase is downstream of 
EGFR signaling, but not FGFR or CB1/2 receptor signaling and is not the proposed 




CHAPTER VI: Results 4 
Characterization of DAGL activity in Cor-1 cells 
6. Is mTOR/p70S6K downstream of EGFR, FGFR and/or eCB signaling? 
6.1. Introduction 
As mentioned in the previous results chapter, there is accumulating evidence, that 
both DAGLα as well as DAGLβ can be phosphorylated, which is a widespread 
mechanism to regulate the activity of numerous enzymes (Olsen et al., 2006).  
Hence it is very likely, that DAGL activity is regulated by phosphorylation, and the 
sole knowledge about expression is not sufficient to understand DAGL function.  
Measuring 2-AG levels is far from trivial and a simple “96-well” plate assay for DAGL 
activity would allow us to investigate what is driving DAGL dependent eCB signaling, 
which kinases might regulate DAGL activity by phosphorylation of and many more 
DAGL related questions.  There recently has been a DAGL activity assay published 
that utilises two independent surrogate substrates (Pedicord et al., 2011).  The 
fluorogenic substrate is called 6, 8-difluoro-4-methylumbelliferyl-octanoate 
(DiFMU), while the chromogenic substrate is called 4-nitrophenol butyrate (PNP).  
The paper describes how DAGL assays were performed on membranes prepared 
from parental and DAGLα transfected HEK293 cells, and I have modified this assay 
for use with Cor-1 cells.  Both substrates were tested for their suitability for 
membrane and whole cell assays and it was confirmed that the expression of 
different DAGL constructs in Cor-1 cell lines leads to an increased DAGL activity.  
Furthermore, this assay was used to establish if the use of EGFR inhibitors, FGFR 
inhibitors, or insulin withdrawal has the ability to change DAGL activity.   
6.2. Optimization of a membrane based DAGL activity assay using the 
surrogate substrate PNP 
As a first step we had to establish that our membrane preparation method enriches 
DAGL.  To do so membranes were prepared from DAGLα-V5 overexpressing V5α7 











An antibody to the V5 epitope tag and an antibody against endogenous DAGLα 
were used to establish the enrichment of DAGLα in the cell membrane fractions.  
An example of a western blot is shown in Figure 6.1.  V5α7 cells express the DAGL-
V5 tagged enzyme at 120kDa and furthermore it is substantially enriched in the 
membrane fraction.  An endogenous DAGLα antibody was used to confirm this 
result (Figure 6.1.B). 
After confirming that DAGLα is enriched in the membrane preparation of the V5α7 
cells, the membranes were used for DAGL activity assays.  The assays were carried 
out in 96-well clear polypropylene plates, buffers appropriate for the respective 
substrates were used and the reaction was followed kinetically using the 
SpectramaxPlus set at a wavelength of 400nm for the substrate PNP and the 
Flexstation using an excitatory wavelength of 360nm and an emission of 450nm for 
the DiFMU substrate.  The reaction rate was calculated based on the linear 
regression of the initial 10min using the SoftMaxPro software and typically the 
mean of 3-4 wells is presented. 
A time course using the membranes from Cor-1 or V5α7 cells at a final assay 
concentration (FAC) of 12.5µg/ml and a substrate concentration of 250µM PNP is 
shown in Figure 6.2, for control membranes and membranes treated with 1µM THL.  
The absorbance at 400nm was measured every 12sec for 10min as has been done 
for all of the following experiments in this section and the mean of three wells is 
presented.  The reaction rate seen for V5α7 membranes is considerably higher than 
that seen with membranes from parental Cor-1 cells.  Moreover, this enhanced 
activity was completed suppressed by THL (Fig 6.2 A).  Use of THL reveals the 
background activity, perhaps driven by other lipases and other enzymes, and when 
this signal was subtracted the enhanced activity in the cells that overexpress DAGL 
was quite considerably higher compared to the parental Cor-1 membranes (Fig 































The effect of varying the membrane  concentrations in the PNP DAGL activity assay 
were established and presented in Figure 6.3 A and B.  Cor-1 and V5α7 membranes 
were used at a range between 50 and 6.25µg/ml FAC ±1µM THL at a PNP 
concentration of 250µM.  The THL sensitivity (presumably DAGLα activity) was only 
seen with membranes isolated from the V5α7 cells, and not with parental cells.  
This further supports the conclusion that the activity is indeed dependent on the 
transgene and suggests that DAGL activity is below a readily detectable value in the 
parental cells.  A membrane concentration of 12.5µg/ml was chosen for all further 
experiments.  At this membrane concentration the reaction rate of the V5α7 
membranes is approximately 4 times higher compared to the parental Cor-1 
membranes, but a bigger difference can be seen at higher membrane 
concentrations. 
We next varied the substrate concentration (Fig 6.2 C and D).  Again, the reaction 
rate was linearly related to substrate concentration with membranes from V5α7 
cells, with no such relationship seen with membranes from parental cells when the 
THL background was subtracted.  Based on the experiments above, it was decided 
to do all further experiments using a PNP substrate concentration of 250µM unless 
otherwise stated, as it is well within the linear range of the assay.  Even though Cor-
1 cells express both DAGL isoforms (Goncalves et al., 2008), the endogenous activity 
levels in Cor-1 cells are relatively small and are below the detection ability of this 
novel DAGL assay, at least in these initial experiments.  The proportion of the 
reaction rate seen for V5α7 membranes, most likely is down to the transgenic 
DAGLα activity. 
We next tested the effects of three DAGL inhibitors on the activity measured in the 
membranes of the parental and transfected Cor-1 cells (Figure 6.4).  OMDM-188 is 
the most potent DAGL inhibitor described to date (Ortar et al., 2008), and this fully 
inhibited the activity measure in the membranes from the DAGLα transfected V5α7 
cells at 100nM.  Again, this compound only had a marginal effect on the much 


















RHC80267 inhibited activity in membranes from the DAGL transfected cells in a 
dose-dependent manner, with a ~50% inhibition seen at 10µM and an almost 
complete inhibition at 100 µM (Fig 6.4 B).  THL was seen to inhibit the differential 
activity seen between membranes obtained from the DAGL transfected cells 
compared to the parental cells (Fig 6C).  Thus three independent DAGL inhibitors 
reduced the activity seen in membranes from DAGL transfected cells back to the 
level seen with membranes from parental cells.  These results further support the 
conclusion that the assay is measuring the activity of the transfected DAGL, and 
confirm relatively low levels of this activity in the parental cells. 
6.3. Optimization of a membrane based DAGL activity assay using the 
substrate DiFMU 
After establishing PNP as a suitable substrate for Cor-1 membrane assays, we 
tested the fluorogenic substrate DiFMU.  A time course using membranes at 
12.5µg/ml and a substrate concentration at 10µM DiFMU is shown in Figure 6.5.  
Using this substrate, the difference between membranes from the parental and 
DAGL transfected cells was relatively small, and the signal was only partially 
inhibited by THL (Figure 6.5).  Attempts to “tease-out” a better differential signal 
between the cells by varying membrane concentration (Fig 6.6 A and B) or substrate 
concentration (Fig 6.6 C and D) showed the best differential to be obtained with 
membranes at 12.5µg/ml and substrate at 10µM.  The highest difference was ~ 2-
fold increase between Cor-1 and V5α7 membranes when the THL background was 
subtracted.  Again three DAGL inhibitors were tested and confirmed that the signal 
can be inhibited by either of them (data not shown) however, results with the non-
fluorogenic substrate were clearly better providing a better signal window due to 
the lower background. 
6.4. Whole cell DAGL activity assay  
We next wanted to determine if the DAGL assays could be adapted for use with on 
a whole cells assay.  A whole cell assay would allow the user to observe the effect of 



























Cor-1 cells and V5α7 cells were seeded into 96-well plates at a cell density of 40,000 
cells/ well and left to attach overnight in growth media.  This cell number was 
chosen based on past experience as it gives ~60-70% cell confluence the next day.  
To conduct the assay, the growth media was carefully replaced with the 
appropriate assay buffer and the surrogate substrates PNP and DiFMU were tested 
on the whole cells. 
6.4.1. Optimization of a whole cell DAGL activity assay using the substrate 
PNP 
A substrate range of 0-500µM PNP was tested in this whole cell assay as can be 
seen in Figure 6.7.  Half of the Cor-1 and V5α7 cells were treated with 25µM THL 
and absorbance was read at 400nm for 10min.  The reaction rates increased with 
increasing substrate concentration, while THL treatment led to a decrease of 
reaction rate in both cell lines (Figure 6.7 A).  The reaction rate in the presence of 
THL was subtracted from the reaction rate seen for the cells alone, which separates 
the reaction rates of Cor-1 and V5α7 cells and at 250µM the reaction rate of V5α7 
cells was about double the reaction rate seen for Cor-1 cells (Figure 6.7 B).  The 
reaction rates for the DAGL transfected cells increased linearly with substrate 
concentration, whereas the reaction rate seen with parental cells did not differ 
between 50 and 500 µM PNPB.  The DAGL transfected cells hydrolysed the 
substrate 2-3 times better than the parental cells at higher substrate 
concentrations, suggesting that this assay can be used to get an index of DAGL 
activity in living cells.  Again, the difference between the DAGL transfected and 
parental cells was abolished by treatment with THL, RHC80267 and OMDM-188 
(data not shown).  However, the high basal rate of substrate hydrolysis seen with 
parental cells was only partially inhibited by the DAGL inhibitors, and this would be 
a confounding factor in the analysis of data obtained with living cells. 
Given the 4 fold window between reaction rates of Cor-1 and V5α7 membranes in 
the membrane based assay, we expected a similar window for the whole cell assay.  
This was not the case, even though a better separation can be achieved by 
subtracting the respective THL backgrounds.  The higher background in cell based 







6.4.2. Optimization of a whole cell DAGL activity assay using the substrate 
DiFMU 
Next we wanted to establish the suitability of the fluorogenic substrate DiFMU in a 
whole cell assay.  Cor-1 cells and V5α7 cells were seeded at a cell density of 40,000 
cells/well and left to attach overnight in growth media.  A substrate range of 0-
40µM DiFMU was tested on the whole cell assay as can be seen in Figure 6.8.  Half 
of the Cor-1 and V5α7 cells were treated with 25µM THL and fluorescence is 
measured using an excitatory wavelength of 360nm and an emission of 450nm for 
10min every 10sec.  The reaction rates were overall proportional to the substrate 
concentration, while THL treatment led to a decrease of reaction rate in both cell 
lines (Figure 6.8).  With this substrate the parental cells showed a slightly higher 
reaction rate compared to V5α7 cells suggesting it is driven by other enzymes, most 
likely other lipases.  
Overall, neither PNP nor DiFMU based whole cell assay were very robust and the 
window between reaction rates of Cor-1 cells and V5α7 cells was smaller compared 
to the membrane based assays.  We therefore decided to do further experiments 
based on the membrane assays. 
6.5. Applying a membrane based DAGL activity assay to compare 
differences in DAGL activity 
6.5.1. Analysing DAGL activity in different Cor-1 cell lines 
Different Cor-1 cell based cell lines were established as mentioned in previous 
chapters.  In brief, V5α7 cells express DAGLα-V5, Mα8 cell express DAGL-V5 with a 
mutation in a putative d-box and V5β5 cells express DAGLβ-V5.  The membrane 
based DAGL assay was chosen to identify, if the overexpressed enzymes are 
functional and by how much they increase the measured reaction rates.  
Membranes from Cor-1, V5α7, Mα8, and V5β5 cells were extracted and plated at 
12.5µg/ml FAC onto a 96-well plate.  Half of the membranes were treated with 1µM 
THL and 250µM PNP was used as a substrate for the performed DAGL activity assay 
(Figure 6.9 A+B).  The absorbance at 400nm was read, the reaction rate was 
normalised to the reaction rate of Cor-1 membranes and data from three 









The relative reaction rates were increased for all the tested membranes from the 
overexpressing cell lines if compared to the native Cor-1 membranes (Figure 6.9 A).  
The reaction rate in the presence of THL was defined as background and subtracted 
from the signal of the uninhibited membranes (Figure 6.9 B).  The relative reaction 
rate of the overexpressing cell line membranes is 4-5 times higher than the relative 
reaction rate of Cor-1 membranes.  This confirms that all three overexpressing cell 
lines express functional DAGL constructs and all membranes reacted to THL 
treatment with a reduced reaction rate.  It furthermore confirms that DAGLα, as 
well as DAGLβ can use PNP as a surrogate substrate and that the d-box mutation in 
Mα8 cells does not abolish DAGL activity. 
The same assay design as described above was used for an assay using DiFMU as a 
surrogate substrate.  The fluorescence is measured using an excitatory wavelength 
of 360nm and an emission of 450nm for 10min, the reaction rate was normalised to 
the Cor-1 reaction rate and data from three different experiments were pooled 
(Figure 6.9 C+D).  The THL background was subtracted from the relative reaction 
rate seen for the membranes on their own and is presented in Figure 6.9 D.  The 
relative reaction rate of V5α7 is approximately doubled in comparison to Cor-1 
membranes and only a very slight increase in the relative reaction rate for Mα8 and 
V5β5 in comparison to Cor-1 membranes was observed.  Overall this ties in with 
previous observations during the optimization of the DiFMU membrane assay 
where only a small window between the parental and transgenic DAGLα expressing 
cell line was observed and we therefore decided to focus on PNP based membrane 
assays to address further questions. 
6.5.2. Is DAGL activity regulated by EGFR, FGFR and/or insulin? 
As described in previous results chapters, one of our aims is to establish what drives 
the eCB signaling in Cor-1 cells.  The three investigated contenders for this role are 
EGF, FGF and InsR signaling and we designed a DAGL activity assay aiming to 
address this question.  V5α7 cells were grown in growth media, treated for 4h with 
100nM AG1478 and 500nM PD173074 (EGFR/FGFR inhibitors respectively) or 



































The membranes from these cells were extracted and plated at 12.5µg/ml FAC onto 
a 96-well plate.  Half of the membranes were treated with 1µM THL and 250µM 
PNP was used as a substrate.  The absorbance is read at 400nm for 10min, the 
reaction rate was normalised to the V5α7 cell reaction rate and data from three 
independent experiments was pooled (Figure 6.10 A+B).  The relative reaction rate 
in the presence of THL was defined as background and subtracted from the relative 
reaction rate of the membranes without THL (Figure 6.10 B).  The relative reaction 
rate is slightly increased for the membranes treated with EGFR/FGFR inhibitors and 
increased by 25-30% in membranes from the cells grown without insulin.  This 
trend however is not significant, but encouraging to further investigate the role of 
insulin on DAGL activity. 
6.6. Conclusions and discussion 
The measurement of the eCBs, 2-AG and anandamide, is challenging and relatively 
time consuming (Gao et al., 2010; Zoerner et al., 2012) and therefore we wanted to 
investigate a recently published DAGL assay using surrogate substrates (Pedicord et 
al., 2011).  Here we tested the surrogate substrates PNP and DiFMU in membrane 
based and whole cell assays using parental and DAGLα transfected Cor-1 cells.   
DAGLα is considerably enriched using a membrane extraction method compared to 
the lysate (Figure 6.1), which is not surprising, as DAGLα is thought to be associated 
with the membrane.  The substrate PNP was tested (Figure 6.2+6.3) on parental 
Cor-1 membranes and membranes from the transgenic DAGLα expressing cell line.  
Only the signal of V5α7 membranes can be convincingly inhibited using THL 
indicating that the DAGLα activity in Cor-1 cells lies below the detection level of this 
assay.  A substrate as well as membrane dependent increase of the reaction rate 
can be seen for V5α7 membranes and on average, a 4 fold difference was seen 
between the reaction rate of Cor-1 cells and V5α7 membranes at a FAC of 
12.5µg/ml and a PNP concentration of 250µM, which are the most commonly used 
concentrations in our experiments.  A bigger difference was seen at higher 
membrane and substrate concentrations.  OMDM-188, THL, and RHC80267 were 
tested on Cor-1 and V5α7 membranes (Figure 6.4) and they inhibited the reaction 
rates.  In the case of OMDM-188 and THL the reaction rate of V5α7 membranes fell 
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below that seen for Cor-1 membranes and this might indicate a slightly different 
background, which is not inhibited by the DAGL inhibitors in Cor-1 compared to 
V5α7 membranes as they are a clonal cell line.   
Membrane assays using DiFMU as a substrate were carried out and the reaction 
rates seen for Cor-1 and V5α7 membranes were very similar (Figure 6.5+6.6).  
Subtracting the "THL background" from the signal, a difference can be seen 
between the parental and the transgenic cells.  However the small difference 
between the two membrane types imposes limitations for the use of DiFMU in Cor-
1 membrane assays (Figure 6.4). 
Given the success using PNP as a surrogate substrate in the membrane based assay, 
we wanted to establish, if PNP can be used in a whole cell assay.  This would allow 
an even quicker mean of screening DAGL activity.  While both cells' DAGL activity 
could be inhibited using THL as well as OMDM-188 and RHC80267 (data not 
shown), the reaction rate seen for Cor-1 cells was very similar to the reaction rate 
seen for V5α7 cells under all conditions (Figure 6.7 A).  A similar result was seen 
when DiFMU was used as a substrate in a Cor-1 whole cell assay (Figure 6.8).  The 
overall lack of robustness and a clear window between parental and transgenic cell 
activity lead to the decision to focus on membrane based assays. 
Next, we wanted to establish if the overexpressing cell lines V5α7, Mα8, and V5β5 
display an increase in DAGL activity.  To do so, we carried out PNP and DiFMU based 
membrane assays.  Using PNP as a substrate, the relative reaction rates of all three 
cell lines were significantly increased compared to Cor-1 membranes (Figure 6.9 
A+B).  This indicates, DAGLβ can use PNP as a surrogate substrate while the 
putative d-box mutation in DAGLα has no fundamental effect on enzyme activity.  
Using DIFMU as a surrogate substrate to carry out the same set of experiments no 
significant difference between relative reaction rates was seen for the different 
Cor-1 cell lines (Figure 6.9 C+D), which is in line with previous observations showing 
a very limited window between Cor-1 and V5α7 membrane reaction rates while 
establishing assay conditions (Figure 6.6).  Therefore this reflects a limitation of 
DiFMU based assays in Cor-1 cells rather than being a reflection on the DAGLs 
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activity status and therefore all further questions were addressed using the PNP 
based membrane assay. 
The EGFR, FGFR, and insulin signaling were explored as possible mechanisms to 
drive eCB signaling in Cor-1 cells (see previous Chapter).  To investigate the direct 
influence on DAGL activity, V5α7 cells were treated with the EGFR and FGFR 
inhibitors or deprived of insulin (Figure 6.10).  EGFR/FGFR inhibitor treatment did 
not fundamentally change DAGL activity, consequently underlining previous results 
in this thesis, that eCB signaling is not influenced significantly by EGF/FGF signaling 
in Cor-1 cells.  Insulin deprivation, however, leads to an increase in DAGL activity 
(Figure 6.10 B).  While not being a significant difference (student t-test), this 
observation is interesting in combination with our previous results and encourages 
to further explore the relationship between insulin and DAGL driven eCB signaling. 
A DAGL surrogate substrate assay based on commercially available substrates 
allows cheap and large scale screens to monitor DAGL activity.  However it has to be 
mentioned, that these results always have to be verified using the native substrate.  
We proposed, that DAGL has a "lid" region, which is potentially capable of limiting 
substrate access to the catalytic side (Reisenberg et al., 2012 ).  Differences in 
substrate size or other properties might allow the substrate to be metabolised by 
DAGL even when the "lid" prevents access to the catalytic side for DAG.  The 
surrogate substrate DiFMU overall failed to be suitable as a surrogate substrate for 
use on Cor-1 membranes in our hands.  However a significant signal window was 
seen for PNP.  It has to be mentioned, that in Cor-1 cells the overexpression of 
DAGLα as well as DAGLβ leads to an increase in signal when PNP is used as the 
surrogate substrate, indicating that it can be used as a surrogate substrate by both 
which might allow to study both DAGLs.  Overall, PNP was a reliable surrogate 
substrate in the membrane based assay and will be utilized for further studies.    
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CHAPTER VII: Discussion  
7. khsdk 
Since the initial stages of eCB research many discoveries have linked this signaling 
pathway with a wide range of physiological processes.  Our lab is particularly 
interested in the effect the eCB system has on adult neurogenesis and have used 
the Cor-1 NSC line in combination with other in vitro and in vivo methods to 
establish a correlation between eCB signaling and progenitor cell proliferation 
(Goncalves et al., 2008).  To gain a better understanding of eCB signaling overall it is 
essential to expand the knowledge about eCB regulation as well as putting it into 
context with the extended signaling network.  DAGLα is at the heart of eCB 
signaling and little is known about its regulation.  It is important to investigate this 
further, as DAGL synthesizes one of the key eCBs. 
 
Figure 7.1: Schematic for the role of DAGL and the CB1/2 receptors in 
proliferation and differentiation 
While DAGL as well as CB1/2 receptor signaling is required for the proliferation of 
neural stem cell proliferation in vitro, no evidence was found indicating that the 
CB1/2 receptors are needed for differentiation of neural stem cells to astrocytes or 
towards a neuronal linage.  
In summary, as part of this thesis the Cor-1 cell line were introduced as a suitable 
model system to investigate eCB signalling.  It was previously used to establish a 
solid basis for investigating the role of the eCB system in proliferation as well as 
migration.  Here we used the Cor-1 cell line to establish the role of the eCB system 
in neuronal and astrocytic differentiation which proved to be not the case.  
Furthermore DAGLα expression levels were established during these differentiation 
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processes and we found, that a rapid reduction of DAGLα occurs during neuronal 
differentiation, while remaining level during astrocytic differentiation.  The 
observed reduction occurs within 24 hours which lead us to be interested in what 
causes the decrease of DAGLα protein expression.  In this context, a d-box motif, 
which can lead to degradation of the protein via the ubiquitin proteasome pathway, 
was detected within the sequence of DAGLα.  No evidence was found supporting 
the hypothesis that the putative d-box causes the rapid reduction of DAGLα during 
neuronal differentiation.  However, first evidence indicates that DAGL can be 
ubiquitinated.  In order to be able to investigate DAGL regulation it is essential to 
measure enzyme activity and a new assay based on two surrogate substrates has 
been published.  The chromogenic substrate was successfully adapted to measure 
DAGL activity in DAGL overexpressing Cor-1 cells and will be a useful tool to address 
further questions.  Both DAGLα and DAGLβ can metabolise the surrogate substrate . 
As mentioned above, a role for the eCB system in Cor-1 proliferation has been 
identified.  It is not known, what the upstream driving mechanisms of the eCB 
system are and EGF, FGF and insulin were investigated as part of this thesis in this 
context.  Microarray and other data indicate, that neither FGF nor EGF are 
upstream of the eCB system.  A subset of transcripts appears to be regulated by the 
EGFR as well as the CB1/2 receptors, which could be explained by a common 
signalling node.  mTOR was suspected to be this signaling node, but evidence was 
found supporting the notion that it is not the signalling node.   
This thesis focuses on DAGL-dependent CB1/2 receptor signaling.  As mentioned in 
the introduction there are non-CB1/2 receptors which are capable of interacting 
with the endocannabinoid.  For that reason it is essential to investigate the roles of 
DAGL and the CB1/2 receptors on the investigated processes.  This has been done 
for example when establishing the role of the eCB system in NSC proliferation 
(Goncalves et al., 2008) where DAGL as well as CB1/2 receptor antagonists were 
utilized.  This approach does not exclude the possibility of non-CB1/2 receptors 
playing a role for NSC proliferation, but it does show a clear role of DAGL 
dependent CB1/2 receptor signalling in NSC proliferation.  Both 2-AG and 
arachidonic acid have been investigated in NSCs as well as the brain and in many 
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contexts their effects remain difficult to separate (Alger and Kim, 2011; Alger, 
2012).  This is another reason why it is important to use a combination of CB1/2 
receptor antagonists and DAGL inhibitors as using. 
7.1. The Cor-1 cells as a model system to investigate eCB signaling 
In the context of neurogenesis research, neurosphere assays have been widely used 
to carry out in vitro assays (Reynolds and Weiss, 1992) as well as being used to 
investigate the role of the eCB system in NSC proliferation (Molina-Holgado et al., 
2007).  In brief NSCs are plated at a low density and give rise to neurospheres.  
While being a useful tool, the disadvantage of neurosphere assays is that of the 
heterogeneous nature of the neurosphere containing NSCs as well as their progeny 
(Reynolds and Weiss, 1992; Reynolds and Rietze, 2005).  Therefore there are 
limitations on researching individual signaling pathways in one of the cell types like 
the NSCs using this assay. 
Another kind of in vitro assay is based on adherent NSC cultures and possibly one of 
their main advantages is their homogenous cell population.  The Cor-1 cells were 
termed NSCs when they were generated and are similar to embryonic stem cells 
(Conti et al., 2005).  Similar adherent rodent and human cell lines with comparable 
expression profiles and behaviour have been generated from foetal as well as adult 
tissue as well as ES cells (Conti et al., 2005; Sun et al., 2008).  Cor-1 cells maintain 
certain aspects of "true" NSCs as they are tripotent and can be grown for an 
extended period of time without differentiation as well as expressing a range of 
NSC markers (Conti et al., 2005; Glaser et al., 2007).   
In order to generate new neurons, NSC cells have to proliferate, migrate to their 
destination, and differentiate into functional cells.  All these processes can be 
investigated using Cor-1 cell assays.  DAGL is expressed in SVZ ependymal and 
proliferating cells and inhibiting DAGL or CB2 results in reduced proliferation of 
cultured NSCs (Goncalves et al., 2008).  These findings were based on the DAGL 
inhibitors RHC80267 and THL.  Since then the DAGL inhibitor OMDM-188 has 
become available to us, which has been shown to have a higher specificity (Ortar et 
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al., 2008).  OMDM-188 was used in a Cor-1 cell based proliferation assay in this 
thesis and supports the importance of DAGL for NSC proliferation. 
The eCB system has been demonstrated to be relevant for some cell 
differentiations.  CB1 receptor activation can enhance progenitor proliferation as 
well as their differentiation into astroglial cells in vitro.  Furthermore, the 
progenitor proliferation and astrogliogenesis are impaired in CB1 KO mice (Aguado 
et al., 2006).  DAGL, 2-AG and MAGL have been shown to be expressed by 
oligodendrocytes throughout different developmental stages and DAGLα and 
DAGLβ were found in cultured oligodendrocyte progenitors.  Furthermore, the 
DAGL inhibitor RHC80267 blocked the maturation of these cells and this process 
might be mediated via the ERK/MAPK pathway (Gomez et al., 2010).  In the chick 
the CB1 expression pattern mirrors neuronal differentiation throughout the early 
developmental stages (Begbie et al., 2004) and the importance of eCB signaling for 
neuronal differentiation is discussed in considerable detail elsewhere (Keimpema et 
al., 2011).  Given the role of eCB signaling for the proliferation and migration of Cor-
1 cells, we wanted to establish, if the eCB system is relevant to Cor-1 cell 
differentiation.  The Cor-1 cells can be differentiated into astrocytes, neurons and 
oligodendrocytes (Conti et al., 2005; Glaser et al., 2007) and we wanted to establish 
the role of eCB signaling for neuronal and astrocytic differentiation but no evidence 
to support this hypothesis was identified.  While endogenous DAGLα expression is 
unchanged by astrocytic differentiation, a reduction in overall DAGLα levels was 
seen upon neuronal differentiation.  At least part of the reduction is based on the 
rapid reduction of DAGLα in Tuj-1 positive interneuron.  It has to be mentioned that 
no such reduction was seen in hippocampal interneurons (PhD thesis, Madeleine 
Oudin) and therefore might be limited to certain types of interneurons.  
Furthermore, Cor-1 cells have been used to research NSC migration elsewhere (PhD 
thesis Madeleine Oudin, Oudin et al., 2011b).   
Cor-1 cell based in vitro findings showing a reduced proliferation when the CB2 
receptor or DAGL were inhibited were mirrored by a drop in progenitor cell 
proliferation in young mice.  Reduced progenitor proliferation in the SVZ 
furthermore led to a smaller number of neuroblasts migrating to the OB (Goncalves 
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et al., 2008).  Using a Cor-1 cell based migration assay a role for eCB signaling in 
Cor-1 cell migration was uncovered.  In vivo experiments confirmed a role of the 
eCB system for some aspects of neuroblast formation such as nucleokinesis and 
length and branching of migratory neuroblast processes (Oudin et al., 2011b).  This 
highlights that the Cor-1 cells overall are an appropriate model system to 
investigate the eCB system and various aspects of neurogenesis.  However, 
considering the importance of the NSC niche for NSCs it has to be stressed that all 
in vitro results need to be confirmed in vivo.   
7.2. Regulation of DAGLα 
The DAGL enzymes can be seen as the switch between DAG and 2-AG signaling.  
Since both molecules have important signaling roles it is reasonable to assume that 
DAGL activity is regulated.  In the past the field of eCB research mainly focused on 
the processes "downstream" of 2-AG and/or anandamide interactions with the 
CB1/2 receptors.  Relatively little focus was put onto the enzymes generating the 
eCBs and to date little is known about DAGL regulation (Reisenberg et al., 2012 ) 
but collective evidence from the literature points towards it and will be discussed in 
more detail below.  
To understand the requirements for DAGL activity is to understand what initiates 
eCB signaling.  To my knowledge, there is no other accurate way to monitor DAGL 
activity other than measuring 2-AG levels, which is a relatively technical, 
chromatography based method (Zoerner et al., 2012).  Therefore it is crucial to 
establish quicker, higher throughput methods as this will help to investigate DAGL 
activity.  A recent paper published two surrogate substrates for a membrane based 
DAGL assay (Pedicord et al., 2011), which was tested for its transferability to Cor-1 
cells in this thesis. The surrogate substrate PNP was successfully established for use 
in Cor-1 cells.  Further testing will be required to establish how comparable the 
surrogate substrate and DAG are, but overall this novel assay is a promising tool 
and will help to understand DAGL activity. 
7.2.1.  DAGL phosphorylation and structural features 
The DAGLs belong to the α/β-hydrolase family with the signature core of an α/β-
sheet consisting of 8 strands connected by helices.  The described feature is located 
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in the catalytic domain of DAGL and contains the catalytic tirade.  Bioinformatic 
analysis revealed a possible "lid" or "cap" loop, which potentially guards the 
hydrophobic catalytic cavity against water, but allows lipid access by opening upon 
membrane absorption (Miled et al., 2003; Reisenberg et al., 2012 ).  There is 
cumulative mass spectrometry data pointing towards phosphorylation of the DAGLs 
within the catalytic domain and the regulatory loop (Wang et al., 2006; Rikova et 
al., 2007; Dephoure et al., 2008; Brill et al., 2009; Mayya et al., 2009; Huttlin et al., 
2010; Hsu et al., 2011).  Therefore it is reasonable to assume, that phosphorylation 
might be involved in DAGL activity (Reisenberg et al., 2012 ).  Moreover, if the 
putative DAGL "lid" indeed regulates access to the catalytic cavity the substrate size 
and other properties are a crucial part of gaining access to the catalytic side.  
 
Figure 7.2: The DAGLα/β phospho map 
The DAGLα/β phospho map is numbered according to the human enzyme and 
represent the currently known phosphorylation sites.  The catalytic side of the 
DAGL enzymes is presented in red, the signature motif in blue and the regulatory 




7.2.2. Ubiquitination and degradation 
It is important to understand DAGL degradation as it might be an additional 
mechanism to transcriptional regulation to allow a tight regulation of DAGL.  A 
"switch" in expression pattern is for example observed between development and 
the adult brain for the DAGLs and is discussed in more detail in the introduction of 
this thesis.  While DAGLα is expressed in the axonal tracts during development in 
the adult it is highly enriched in dendrites (Bisogno et al., 2003).  The degradation of 
DAGLα on the protein level -to the best of my knowledge-has not been 
investigated.  Based on an observation in the context of neuronal differentiation of 
Cor-1 cells, we developed an interest in this process.  In this report some 
preliminary results point towards ubiquitination of DAGLα in Cor-1 cells.  Since the 
ubiquitination was seen in an overexpressing cell line it is possible that the 
ubiquitination is part of a regulatory mechanism to manage the higher than normal 
DAGLα protein levels or it might account for an increased mis-folding of the DAGLα 
enzyme in this context.  While requiring further investigation this observation is still 
interesting as it is a potential regulatory mechanism.  In the context of membrane 
proteins, ubiquitination has been shown to lead to degradation via the lysosome 
pathway (Piper and Luzio, 2007) and might be part of the mechanism to regulate 
DAGL levels.   
7.2.3. Palmitoylation 
S-Palmitoylation is a reversible and dynamic form of post translational modification, 
which is regulated through protein acyltransferase and protein acylthioesterases.  It 
describes the linkage of a long -chain fatty acid to a cysteine residue of membrane 
protein and increases the hydrophobicity of the protein and enhances the 
membrane association.  Especially, its reversibility makes it versatile and 
palmitoylation has been shown to be involved in a wide range of processes such as 
protein-protein interaction, subcellular trafficking and synapse plasticity (Smotrys 
and Linder, 2004; Resh, 2006).  In the latter, it regulates a variety of aspects of 
neuronal protein trafficking (Fukata and Fukata, 2010).  One prominent member of 
the lipase family that is known to be palmitoylated is Phospholipase D (PLD).  
Palmitoylation has been shown to be essential for its correct membrane localization 
and endocytosis (Du et al., 2003).  It furthermore has been shown that a lack of 
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palmitoylation impairs mono-ubiquitination and thereby most likely its subcellular 
trafficking (Yin et al., 2010).  DAGL has been identified in a neural palmitoyl-
proteomics screen as a candidate protein for palmitoylation (Kang et al., 2008).  A 
further indication for a post translational modification in general is a different 
molecular weight in different brain regions such as the hippocampus and 
cerebellum (unpublished observation and Yoshida et al., 2006).  Moreover, DAGLα 
was identified to be localized in lipid rafts (Rimmerman et al., 2008), which are 
known to be an assembly point for palmitoylated proteins and often are involved in 
efficient signal transduction (Resh, 2006).  Taken together these publications make 
palmitoylation of DAGL highly possible and it might be a potential process which is 
part of its regulation. 
7.2.4. Transcriptional regulation of DAGL 
The core promoter of mammalian DAGLα and its regulatory elements have been 
identified and an enhancer and a suppressor region were recognized.  Utilizing 
deletion analysis, two promoting elements including a GC-box were found and 
shown to particularly be involved in promoting expression in NSCs.  Out of the three 
candidate transcription factors (growth response element 1, zinc finger DNA-
binding protein 89 and specific protein 1 (Sp1)) only the later was shown to bind to 
the GC-box.  Differentiation of a NSC line towards a GABAergic neuronal phenotype 
showed a drastic down-regulation of DAGLα, which was mirrored by a down-
regulation of SP1 (Walker et al., 2009).  Despite these initial findings, the 
transcriptional regulation of DAGLα/β is relatively unexplored and requires further 
investigations. 
7.3. The DAGLα signaling network 
7.3.1. What drives eCB/DAGL signaling? 
In order to understand DAGL/eCB signaling in NSCs, it is essential to understand 
what drives this signaling pathway.  In neuronal growth cones the FGFR was 
demonstrated to be upstream of DAGL/eCB signaling (Williams et al., 2003) It has 
also been shown that EGF and FGF-2 are mitogens essential for the proliferation 
and maintenance of NSCs in vitro as well as in vivo and both mitogens are 
downregulated during aging (Enwere et al., 2004; Shetty et al., 2005). This coincides 
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with a reduced utilization of eCB signaling in older mice.  While DAGL expression 
remains relatively unchanged in the SVZ of older animals, CB2 agonists can increase 
proliferation in these older mice, while having no fundamental effect on the same 
cells in younger animals (Goncalves et al., 2008).  Therefore it could be 
hypothesized, that the reduction in eCB signaling in older animals might reflect a 
reduced upstream signaling stimulus.  Comparing the transcriptional response of 
eCB signaling with that of EGFR or FGFR inhibition little correlation was seen 
between these signaling pathways.  Additionally CB1 and/or CB2 receptor agonists 
were unable to recover reduced Cor-1 proliferation caused by a reduction in EGF 
concentration.  These and other results indicate that neither EGF nor FGF2 signaling 
have a considerable influence on eCB signaling in Cor-1 cells. 
Stem cells can react to metabolic fluctuations (Speder et al., 2011) and even though 
InsR and IGFR expression within the brain regions, such as the OB, hypothalamus 
and hippocampus was established in the late 70th (Havrankova et al., 1978; Unger 
et al., 1989), the role of insulin signaling was more recently linked to brain cell 
progenitor proliferation (Hodge et al., 2004; Popken et al., 2004; Lehtinen et al., 
2011).  Growth factor signaling, especially via the IGFR, and progenitor cell division 
were linked by different groups (Baker et al., 1993; Hodge et al., 2004; Popken et 
al., 2004; Liu et al., 2009).  IGF-1 was implied to be involved in mammalian NSC 
division (Mairet-Coello et al., 2009) and identified to drive proliferation within the 
embryo (Joseph D'Ercole and Ye, 2008) as well as proliferation in the adult 
mammalian brain (Anderson et al., 2002).  In this thesis I have shown that insulin 
withdrawal leads to a reduced Cor-1 cell proliferation, which can be partly 
recovered using CB1/2 receptor agonists.  However CB1/2 receptor antagonists can 
further decrease Cor-1 cell proliferation indicating that while having an effect on 
eCB mediated proliferation, insulin cannot fully account for what is driving eCB 
signaling.   
A so far not investigated candidate to drive eCB signaling is progesterone.  Gonadal 
hormones have been linked to gliosis (Arevalo et al., 2012) and the eCB system is 
targeted by estradiol in the context of reactive gliosis regulation.  CB1 and CB2 
receptor antagonists moreover are capable of reducing the estradiol effect on 
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reactive astrocytes (Lopez Rodriguez et al., 2011) therefore establishing a link 
between gonadal hormones and eCB signaling.  Progesterone also has been linked 
to the eCB system and while commonly being associated with women, it is also 
present in men.  Progesterone is involved in maintenance of eCB protein levels and 
FAAH can be stimulated by progesterone and leptin in some cell lines (Gasperi et 
al., 2005; Karasu et al., 2011).  It has also been reported that progesterone levels 
reduce with aging (Barron and Pike, 2012) allowing the possibility that this molecule 
may drive the eCB signaling pathway (see above).  Progesterone is present n the 
Cor-1 cell growth media and it would be interesting to investigate a possible 
relationship between progesterone and eCB signaling in Cor-1 cells.   
Moreover, Cor-1 cells do not proliferate well in low cell density conditions 
(unpublished observation), which indicates that the cells secrete certain messenger 
substances themselves, which might drive eCB signaling in Cor-1 cells.   
7.3.2. Which signaling pathways are affected by DAGL activity? 
In this thesis, DAGLα has been explored as part of the eCB pathway.  The DAGLs 
however are in a prime location to influence more than one signaling pathway as 
they influence the steady state levels of different lipid messengers and via them a 
large number of other enzymes.  In some species such as Drosophila, DAGL is 
expressed in the absence of an orthologue to the vertebrate CB receptors (Elphick 
and Egertova, 2005), which might suggest that they are relevant in non-eCB 
contexts. 
Upon GPCR (G-protein coupled receptor) and/or RTK stimulation DAG is hydrolysed 
from phosphatidylinositol 4,5-bisphosphate (Brose et al., 2004).  The DAGL enzymes 
then synthesis 2-AG from DAG; thereby influencing the levels of these molecules 
locally.  DAG has a wide range of roles within the cell and it can act either as a 
substrate to DAGLα/β as discussed here or other enzymes such as DAG Kinase 
(DAGK).  DAGK phosphorylates DAG to generate phosphatidic acid (PA) which might 
have signaling roles (Luo et al., 2004).  Perhaps even more importantly, DAG 
regulates a multitude of enzymes most prominently by activation of the PKCs 
(Mellor and Parker, 1998).  Therefore through these mechanisms alone, the DAGLs 
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indirectly influence an array of cellular activities such as cell growth and gene 
transcription via DAG (Mellor and Parker, 1998; Luo et al., 2004).   
The DAGLs were first discovered in the context of arachidonic acid release from 
mast and platelet cells (Prescott and Majerus, 1983; Allen et al., 1992).  In this 
context 2-AG is hydrolysed by MAGL to arachidonic acid, which is a second 
messenger molecule.  Amongst other roles arachidonic acid serves as a precursor to 
produce eicosanoids and can be utilized by enzymes such as COX, which generate 
the prostanoid prostaglandin H2 (Rapoport, 2008).  In another context, arachidonic 
acid can be hyperoxidated by the liopoxygenases as part of the inflammatory 
response (Harman et al., 2004).  Despite arachidonic acid levels being produced via 
different pathways such as via members of the phospholipase A2 family (Rapoport, 
2008), the DAGL enzymes contribute significantly to the arachidonic acid levels via 
MAGL.  The recently generated DAGL KO animals underline the importance of the 
DAGL/MAGL pathway for arachidonic acid steady state levels as has been 
demonstrated in DAGLα KO mice where an ~80% reduction in arachidonic acid 
levels was observed in the brain and spinal cord with a similar reduction in 2-AG 
levels.  In adipose tissue however, despite a 50% reduction in 2-AG levels, the 
arachidonic acid levels remained unaltered (Gao et al., 2010) highlighting the 
importance of DAGL for arachidonic acid synthesis in the brain. 
Therefore it always has to be kept in mind that while it is tempting to think about 
enzymes and signaling molecules in the context of a single signaling cascade, there 
is a vast amount of interactions and overlaps between signaling pathways.  
Furthermore the relationship with other signaling networks underlines that the 
regulation of the DAGL enzymes is essential to understand in more contexts than 
just in relation to eCB signaling. 
7.3.3. The eCB system and what we still do not know 
DAGLα expression and its' roles in various contexts is relatively well characterized, 
while little is known about DAGLβ.  Studies relying on DAGL inhibitors like THL or 
RHC80267 do not differentiate between the two enzymes at all and therefore 
cannot be used to address this question.  DAGLα/β KO studies revealed a greater 
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role for DAGLα in the brain, while DAGLβ seems to have a higher relevance to the 
liver (Gao et al., 2010).  Further studies in these KO animals should prove to be a 
potent tool to further investigate the differences between the DAGL enzymes (Gao 
et al., 2010; Tanimura et al., 2010).  Considering the many roles of DAGL signaling, it 
is somewhat surprising that the DAGL KO animals are relatively normal.  To what 
extend can the DAGLs stand in for one another?  The generation of double 
DAGLα/β KO mice might help to address this question. 
It furthermore is unclear how the eCBs are released and/or taken up by cells.  Is this 
an active process?  Are some of the enzymes which are part of the eCB system 
involved in this?  The eCBs are thought to be produced "on demand" (Marsicano et 
al., 2003), and unlike peptide messengers it is not thought to be possible to store 
these lipophilic molecules in vesicles.  Considering the lack of information on these 
topics it could be proposed, that the eCB also could be produced and released "on 
demand" rather than being produced on demand (Alger, 2012).   
It is the centre of many discussions to what extend anandamide or 2-AG mediated 
certain processes and this thesis focused very much on DAGL/2-AG mediate eCB 
signaling.  The DAGL KO animals were thought to be able to give a final answer to 
the 2-AG vs. anandamide related questions.  However anandamide levels were 
significantly changed in the brain of DAGLα KO mice and a trend was seen in DAGLβ 
KO mice (Gao et al., 2010).  This highlights that the eCB system is interwoven to a 
high level and careful studies have to be taken to further separate 2-AG and 
anandamide functions.   
7.4. Future directions 
In order to further understand eCB signaling it is necessary to understand when and 
where DAGL synthesizes 2-AG.  Most research in the field of the DAGL enzymes 
currently does not distinguish between expression of the enzymes and their 
activity.  To investigate this further it is essential to have appropriate methods to 
assess DAGL activity.  While it is possible to measure 2-AG levels with a combination 
of chromatographic techniques, this requires the suitable equipment, expertise and 
is relatively time consuming.  Furthermore such a technique does not distinguish 
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between DAGLα and β activity.  A surrogate DAGLα substrate assay has been 
published recently (Pedicord et al., 2011) and one of the two published substrates 
was successfully adapted to the Cor-1 cell line.  Despite requiring further research 
to comparable the native and the surrogate substrate, this is a highly promising 
new tool.  In the context of DAGL phosphorylation it might help to determine the 
effect of different phosphorylation events on DAGL activity and moreover might 
help to identify which kinases are involved in this process.  In relation to the 
question what is driving DAGL dependent eCB signaling it will allow a quicker form 
of screening potential candidates.  
Much accumulative evidence points towards DAGL being phosphorylated and this 
phosphorylation might be associated with enzyme activity (Reisenberg et al., 2012 
).  It would be immensely interesting to explore this further, as phosphorylation 
almost always translates into a change of enzymatic activity.  While identifying 
phosphorylation sites is far from trivial (Mann, Ong et al. 2002; Rigbolt and Blagoev 
2012) it would be a considerable step towards understanding DAGL activity and 
experiments exploring DAGL phosphorylation are currently undertaken by our lab.  
Moreover, several phosphorylation sites have been predicted (Reisenberg et al., 
2012 ) and 5 sites were selected for further analysis by our lab.  Phospho-DAGLα 
antibodies were generated, but more experiments are needed to determine the 
phospho specific nature of these antibodies as well as establishing connections to 
possible roles of these potential phosphorylation events.  In summary, two tools to 
establish DAGL activity are currently being investigated by our lab potentially 
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